

## Supplementary Information

### Unexpected assembly machinery for 4(3*H*)-quinazolinone scaffold synthesis

Xi-Wei Chen<sup>1</sup>, Li Rao<sup>1</sup>, Jia-Li Chen<sup>1</sup> and Yi Zou<sup>\*,1</sup>

<sup>1</sup> College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, P. R. China

\* E-mail: [zouyi31@swu.edu.cn](mailto:zouyi31@swu.edu.cn)

## Table of contents

<b>1. Supplementary Methods</b> .....	5
1.1 Strains and culture conditions.....	5
1.2 Isolation of the gDNA and cDNA synthesis.....	5
1.3 Plasmid construction .....	5
1.4 The protein expression and purification in <i>E. coli</i> .....	7
1.5 The preparation and transformation of <i>A. nidulans</i> protoplasts.....	8
1.6 MALDI-TOF mass data acquisition .....	9
1.7 Bioinformatic analysis.....	10
1.8 Purification and structural characterization of compounds .....	11
<b>2. Supplementary Tables</b> .....	14
<b>Supplementary Table 1.</b> Plasmids used in this study.....	14
<b>Supplementary Table 2.</b> Products from gene ( <i>chyC</i> , <i>chyE</i> and <i>chyH</i> ) individual KO mutant of <i>P. chrysogenum</i> . .....	16
<b>Supplementary Table 3.</b> Analysis of <i>ftchy</i> gene cluster from <i>F. tricinctum</i> .....	17
<b>Supplementary Table 4.</b> HRMS data of compounds in this study .....	18
<b>Supplementary Table 5.</b> NMR data of compound <b>1</b> in DMSO- <i>d</i> <sub>6</sub> .....	20
<b>Supplementary Table 6.</b> NMR data of compound <b>2</b> in DMSO- <i>d</i> <sub>6</sub> .....	21
<b>Supplementary Table 7.</b> NMR data of compound <b>3</b> in DMSO- <i>d</i> <sub>6</sub> .....	22
<b>Supplementary Table 8.</b> NMR data of compound <b>4</b> in DMSO- <i>d</i> <sub>6</sub> .....	23
<b>Supplementary Table 9.</b> NMR data of compound <b>5</b> in DMSO- <i>d</i> <sub>6</sub> .....	24
.....	24
<b>Supplementary Table 10.</b> NMR data of compound <b>6</b> in DMSO- <i>d</i> <sub>6</sub> .....	25
<b>Supplementary Table 11.</b> NMR data of compound <b>7</b> in DMSO- <i>d</i> <sub>6</sub> .....	26
<b>Supplementary Table 12.</b> NMR data of compound <b>8</b> in DMSO- <i>d</i> <sub>6</sub> .....	27
<b>Supplementary Table 13.</b> NMR data of compound <b>9</b> in DMSO- <i>d</i> <sub>6</sub> .....	28
<b>Supplementary Table 14.</b> NMR data of compound <b>10</b> in DMSO- <i>d</i> <sub>6</sub> .....	29
<b>Supplementary Table 15.</b> NMR data of compound <b>11</b> in DMSO- <i>d</i> <sub>6</sub> .....	30
<b>Supplementary Table 16.</b> NMR data of compound <b>14</b> in DMSO- <i>d</i> <sub>6</sub> .....	31
<b>3. Supplementary Figures</b> .....	32
<b>Supplementary Fig. 1</b> Marketed drugs with 4(3 <i>H</i> )-quinazolinone scaffold.....	32
<b>Supplementary Fig. 2</b> Representative natural 4(3 <i>H</i> )-quinazolinone peptidyl alkaloids from fungi. ....	33
<b>Supplementary Fig. 3</b> Representative natural 4(3 <i>H</i> )-quinazolinone alkaloids from plants and bacteria. ....	34
<b>Supplementary Fig. 4</b> Construction of plasmids for overexpression of <i>ftchy</i> cluster in <i>A. nidulans</i> .....	35
<b>Supplementary Fig. 5</b> Confirmation of the on-pathway intermediates of <b>1</b> by chemical feeding experiments. ....	36
<b>Supplementary Fig. 6</b> SDS-PAGE of proteins purified from <i>E. coli</i> BL21 in this study. ....	37
<b>Supplementary Fig. 7</b> ftChyC-catalysed reduction or dehydrogenation reactions with different substrates .....	38
<b>Supplementary Fig. 8</b> Schematic diagrams of ftChyA and its mutants. ....	39
<b>Supplementary Fig. 9</b> Time-course assays of the stability of <b>10</b> .....	40
<b>Supplementary Fig.10</b> LC-MS analyses of the <i>AN-ftchyA</i> with feeding different concentrations of Ant.....	41
<b>Supplementary Fig. 11</b> Sequence clustering analysis of the ftChyA-C <sub>1</sub> and ftChyA-C <sub>T</sub> with other fungal C domains .....	42

<b>Supplementary Fig. 12</b> Sequences alignments of ftChyA-C <sub>1</sub> with other identified fungal NRPS C domains.....	43
<b>Supplementary Fig. 13</b> The genome-mined homologous <i>chy</i> clusters from different fungi. ...	44
<b>Supplementary Fig. 14</b> Sequence alignments of ftChyA-C <sub>T</sub> with homologous domains from other <i>chy</i> clusters. ....	45
<b>Supplementary Fig. 15</b> The ftChyA-C <sub>T</sub> domain is essential for catalysing the formation of <b>10</b> and <b>3</b> .....	47
<b>Supplementary Fig. 16</b> Bioinformatic analysis of ftChyD .....	48
<b>Supplementary Fig. 17</b> Biochemical confirmation of the amidation of ftChyD towards <b>3</b> .....	49
<b>Supplementary Fig. 18</b> The kinetic parameters of ftChyD toward <b>3</b> and <b>10</b> .....	50
<b>Supplementary Fig. 19</b> Sequence alignments of ftChyE with homologous enzymes and other identified glutaminase subunits of class I glutamine amidotransferases .....	51
<b>Supplementary Fig. 20</b> LC-MS analysis of the <i>AN-ftchyACDEHM</i> in H <sub>2</sub> <sup>18</sup> O-medium showing the oxygen atom of the α-OH group of <b>1</b> could be from water .....	52
<b>Supplementary Fig. 21</b> Conserved domain analysis of ftChyH and ftChyM.....	53
<b>Supplementary Fig. 22</b> Sequence clustering analysis of ftChyM with other fungal α-ketoglutarate dependent dioxygenases .....	54
<b>Supplementary Fig. 23</b> The biochemical assays of ftChyM with different substrates .....	55
<b>Supplementary Fig. 24</b> The biochemical assays of ftChyM with <b>11</b> in ~80% H <sub>2</sub> <sup>18</sup> O-Tris-HCl buffer .....	56
<b>Supplementary Fig. 25</b> The proposed mechanism of the (a) ftChyM-catalyzed C-N bond oxidative cleavage <b>11</b> to form <b>4</b> ; (b) the ftChyM-catalyzed oxidative deamination of <b>2</b> to form <b>4</b> ; (c) the alkaline-induced spontaneous C-2-N-3 bond closure of <b>4</b> to form <b>6</b> . ....	57
<b>Supplementary Fig. 26</b> Time-course assays of the spontaneous conversion of <b>4</b> to <b>6</b> .....	58
<b>Supplementary Fig. 27</b> Spontaneous cyclization of compound <b>2</b> , <b>5</b> and <b>4</b> in Tris-HCl buffer (pH 7.5).....	59
<b>Supplementary Fig. 28</b> Biochemical confirmation of the function of ftChyH .....	60
<b>Supplementary Fig. 29</b> SDS-PAGE analyses of the expression of ftChyH-His, ftChyH-MBP and ftChyH-GST in <i>E. coli</i> BL21, respectively.....	61
<b>Supplementary Fig. 30</b> Biochemical assay of ftChyM with <b>14</b> <i>in vitro</i> .....	62
<b>Supplementary Fig. 31</b> LC-MS analyses of the <i>A. nidulans</i> with feeding <b>2</b> showing that <b>2</b> was converted to <b>7</b> by an unknown acetyltransferase of <i>A. nidulans</i> .....	63
<b>Supplementary Fig. 32</b> HRMS spectrum (positive ionization) of compound <b>1</b> .....	64
<b>Supplementary Fig. 33</b> HRMS spectrum (positive ionization) of compound <b>2</b> .....	64
<b>Supplementary Fig. 34</b> HRMS spectrum (positive ionization) of compound <b>3</b> .....	65
<b>Supplementary Fig. 35</b> HRMS spectrum (positive ionization) of compound <b>4</b> .....	65
<b>Supplementary Fig. 36</b> HRMS spectrum (positive ionization) of compound <b>5</b> .....	66
<b>Supplementary Fig. 37</b> HRMS spectrum (positive ionization) of compound <b>6</b> .....	66
<b>Supplementary Fig. 38</b> HRMS spectrum (positive ionization) of compound <b>7</b> .....	67
<b>Supplementary Fig. 39</b> HRMS spectrum (positive ionization) of compound <b>8</b> .....	67
<b>Supplementary Fig. 40</b> HRMS spectrum (positive ionization) of compound <b>9</b> .....	68
<b>Supplementary Fig. 41</b> HRMS spectrum (positive ionization) of compound <b>10</b> .....	68
<b>Supplementary Fig. 42</b> HRMS spectrum (positive ionization) of compound <b>11</b> .....	69
<b>Supplementary Fig. 43</b> HRMS spectrum (positive ionization) of compound <b>14</b> .....	69
<b>Supplementary Fig. 44</b> HRMS spectrum (positive ionization) of compound Ant-Me- <b>3</b> . ....	70
<b>Supplementary Fig. 45</b> HRMS spectrum (positive ionization) of compound Ant-Me- <b>10</b> . ....	70
<b>Supplementary Fig. 46</b> <sup>1</sup> H NMR spectrum of compound <b>1</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz).....	71
<b>Supplementary Fig. 47</b> <sup>13</sup> C NMR spectrum of compound <b>1</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	72

<b>Supplementary Fig. 48</b>	<sup>1</sup> H NMR spectrum of compound <b>2</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz).....	73
<b>Supplementary Fig. 49</b>	<sup>13</sup> C NMR spectrum of compound <b>2</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	74
<b>Supplementary Fig. 50</b>	HMBC spectrum of compound <b>2</b> in DMSO- <i>d</i> <sub>6</sub> .....	75
<b>Supplementary Fig. 51</b>	HSQC spectrum of compound <b>2</b> in DMSO- <i>d</i> <sub>6</sub> .....	76
<b>Supplementary Fig. 52</b>	<sup>1</sup> H- <sup>1</sup> H-COSY spectrum of compound <b>2</b> in DMSO- <i>d</i> <sub>6</sub> .....	77
<b>Supplementary Fig. 53</b>	<sup>1</sup> H NMR spectrum of compound <b>3</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz).....	78
<b>Supplementary Fig. 54</b>	<sup>13</sup> C NMR spectrum of compound <b>3</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	79
<b>Supplementary Fig. 55</b>	HMBC spectrum of compound <b>3</b> in DMSO- <i>d</i> <sub>6</sub> .....	80
<b>Supplementary Fig. 56</b>	HSQC spectrum of compound <b>3</b> in DMSO- <i>d</i> <sub>6</sub> .....	81
<b>Supplementary Fig. 57</b>	<sup>1</sup> H- <sup>1</sup> H-COSY spectrum of compound <b>3</b> in DMSO- <i>d</i> <sub>6</sub> .....	82
<b>Supplementary Fig. 58</b>	<sup>1</sup> H NMR spectrum of compound <b>4</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz).....	83
<b>Supplementary Fig. 59</b>	<sup>13</sup> C NMR spectrum of compound <b>4</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	84
<b>Supplementary Fig. 60</b>	<sup>1</sup> H NMR spectrum of compound <b>5</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz).....	85
<b>Supplementary Fig. 61</b>	<sup>13</sup> C NMR spectrum of compound <b>5</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	86
<b>Supplementary Fig. 62</b>	<sup>1</sup> H NMR spectrum of compound <b>6</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz). ....	87
<b>Supplementary Fig. 63</b>	<sup>13</sup> C NMR spectrum of compound <b>6</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	88
<b>Supplementary Fig. 64</b>	<sup>1</sup> H NMR spectrum of compound <b>7</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz).....	89
<b>Supplementary Fig. 65</b>	<sup>13</sup> C NMR spectrum of compound <b>7</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	90
<b>Supplementary Fig. 66</b>	<sup>1</sup> H NMR spectrum of compound <b>8</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz).....	91
<b>Supplementary Fig. 67</b>	<sup>13</sup> C NMR spectrum of compound <b>8</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	92
<b>Supplementary Fig. 68</b>	<sup>1</sup> H NMR spectrum of compound <b>9</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz).....	93
<b>Supplementary Fig. 69</b>	<sup>13</sup> C NMR spectrum of compound <b>9</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	94
<b>Supplementary Fig. 70</b>	<sup>1</sup> H NMR spectrum of compound <b>10</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz).....	95
<b>Supplementary Fig. 71</b>	<sup>13</sup> C NMR spectrum of compound <b>10</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	96
<b>Supplementary Fig. 72</b>	HMBC spectrum of compound <b>10</b> in DMSO- <i>d</i> <sub>6</sub> .....	97
<b>Supplementary Fig. 73</b>	HSQC spectrum of compound <b>10</b> in DMSO- <i>d</i> <sub>6</sub> .....	98
<b>Supplementary Fig. 74</b>	<sup>1</sup> H- <sup>1</sup> H COSY spectrum of compound <b>10</b> in DMSO- <i>d</i> <sub>6</sub> .....	99
<b>Supplementary Fig. 75</b>	DEPT-135° spectrum of compound <b>10</b> in DMSO- <i>d</i> <sub>6</sub> .....	100
<b>Supplementary Fig. 76</b>	<sup>1</sup> H NMR spectrum of compound <b>11</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz).....	101
<b>Supplementary Fig. 77</b>	<sup>13</sup> C NMR spectrum of compound <b>11</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	102
<b>Supplementary Fig. 78</b>	HMBC spectrum of compound <b>11</b> in DMSO- <i>d</i> <sub>6</sub> .....	103
<b>Supplementary Fig. 79</b>	HSQC spectrum of compound <b>11</b> in DMSO- <i>d</i> <sub>6</sub> .....	104
<b>Supplementary Fig. 80</b>	<sup>1</sup> H- <sup>1</sup> H COSY spectrum of compound <b>11</b> in DMSO- <i>d</i> <sub>6</sub> .....	105
<b>Supplementary Fig. 81</b>	DEPT-135° spectrum of compound <b>11</b> in DMSO- <i>d</i> <sub>6</sub> .....	106
<b>Supplementary Fig. 82</b>	<sup>1</sup> H NMR spectrum of compound <b>14</b> in DMSO- <i>d</i> <sub>6</sub> (400 MHz).....	107
<b>Supplementary Fig. 83</b>	<sup>13</sup> C NMR spectrum of compound <b>14</b> in DMSO- <i>d</i> <sub>6</sub> (100 MHz).....	108
<b>Supplementary Fig. 84</b>	An efficient self-circulation system among ftChyA, ftChyD and ftChyM-catalysed reactions.....	109
<b>4. Supplementary References</b>	.....	110

# 1. Supplementary Methods

## 1.1 Strains and culture conditions

*Fusarium tricinctum* CGMCC 3.4731 was cultured at 25 °C, 7 days on PDA medium (26 g/L Potato Dextrose Water, 2% agar) for sporulation or culture at 25 °C on PDB medium for 4 days to extract genome DNA (gDNA). *A. nidulans* L08030 was culture at 37 °C for 3-4 days on solid CD medium (10 g/L glucose, 50 mL/L 20 × nitrate salts, 1 mL/L trace elements, 20 g/L agar) containing 10 mM uridine, 5 mM uracil, 1 µg/mL pyridoxine HCl and 0.25 µg/mL riboflavin for sporulation. The *A. nidulans* mutants was culture at 25 °C for 3.5 days on solid CD-ST medium (20 g/L starch, 10 g/L casein hydrolysate (acid), 50 mL/L nitrate salts, 1 mL/L trace elements, 20 g/L Agar) for heterologous expression and compounds production.

## 1.2 Isolation of the gDNA and cDNA synthesis

*Fusarium tricinctum* was cultured in PDB medium (26 g/L Potato Dextrose Water) at 25 °C and 220 rpm for 4 days. The mycelium was collected and used for gDNA extraction by Cetyltrimethylammonium Bromide (CTAB) method (20 g/L CTAB, 81.8 g/L NaCl, 186.1 g /L Na<sub>2</sub>EDTA·2H<sub>2</sub>O and 0.1 M Tris-HCl pH 8.0). The total RNA of the *A. nidulans*:*ftchy* was isolated from the strain grown in liquid CD-ST production medium (20 g/L starch, 20 g/L casein hydrolysate, 50 mL/L nitrate salts and 1 mL/L trace elements) at 25 °C and 220 rpm for 3 days. RNA was extracted by TRIZOL<sup>®</sup> Reagent (Ambion), followed by cDNA reverse transcription with the Transcriptor First Strand cDNA Synthesis Kit (Roche).

## 1.3 Plasmid construction

The sequence of *ftchy* gene cluster is deposited in GenBank under accession number OP651004. The gDNA sequences of *ftchy* gene, the protein sequences of ftChy protein, the primer sequences are listed in the Source Data file. The plasmids are summarized in **Supplementary Table 1**.

To construct the expression plasmids of *ftchyA~H* genes for *A. nidulans*, each gene with its terminator (~ 400 bp) was amplified from the gDNA of *F. tricinctum* CGMCC 3.4731 by PCR using primer pairs pANR-*ftchyA*-F1/R1, pANR-*ftchyA*-F2/R2, pANR-*ftchyA*-F3/R3, pANU-*ftchyC*-F/R, pANU-*ftchyD*-F/R, pANU-*ftchyE*-F/R, pANP-*ftchyM*-F/R, pANP-*ftchyH*-F/R, pANU-*ftchyC*-F/R2, pANU-*ftchyH*-F/R2, pANP-*ftchyM*-F2/R yielding plasmids pIM 3201-3206, through yeast homologous recombination in *S. cerevisiae* BJ5464-NpgA. The *glaA*, *gpdA* and *amyB* promoters were amplified from vectors pANU, pANR and pANP by using primer pairs *glaA*-F/*glaA*-R, *gpdA*-F/*gpdA*-R and *amyB*-F/*amyB*-R, respectively. Gene *ftchyA* was cloned into vector pANR with *gpdA* promoter yielding plasmid pIM 3201. Genes *ftchyC*, *ftchyD* and *ftchyE* were cloned into vector pANU yielding plasmid pIM 3202, while the promoters *gpdA*, *glaA* and *amyB* were used for *ftchyC*, *ftchyD* and *ftchyE*, respectively.

Genes *ftchyM* and *ftchyH* were cloned into vector pANP yielding plasmid pIM 3203, while the promoters *gpdA* and *amyB* were used for *ftchyM* and *ftchyH*, respectively. Genes *ftchyC* and *ftchyD* were cloned into vector pANU yielding plasmid pIM 3204, while the promoters *gpdA* and *glaA* were used for *ftchyC* and *ftchyD*, respectively. Genes *ftchyH* and *ftchyM* were cloned into vector pANP with the promoter *amyB* yielding plasmid pIM 3205 and pIM 3206, respectively.

To express *ftchyA* in *E. coli* BL21, intron-free *ftchyA* was cloned from the cDNA of *A. nidulans* containing *ftchy* cluster using the primer pairs pYEU-*ftchyA*-F1/R1, pYEU-*ftchyA*-F2/pANR-*ftchyA*-R1, pANR-*ftchyA*-F2/R2, pANR-*ftchyA*-F3/pYEU-*ftchyA*-R2. The corresponding overlapping fragments were ligated to vector pYEU by yeast homologous recombination to obtain plasmid pIM 3207. The plasmid pIM 3207 was further digested with *BamH* I and *EcoR* I to obtain *ftchyA* and subsequently inserted into the *BamH* I and *EcoR* I digested pColdI (an expression vector with His tag on N-terminus) to yield plasmid pIM 3208. The mutated expression plasmids pIM 3209-3211 were constructed through yeast homologous recombination in *S. cerevisiae* BJ5464-NpgA. The mutated fragments were amplified by PCR using primer pairs pYEU-*ftchyA*-F1/pANR-*ftchyA*-R1, pANR-*ftchyA*-F2/pYEU-*ftchyA*-C<sub>1</sub>-H<sub>987A</sub>-R, pYEU-*ftchyA*-C<sub>1</sub>-H<sub>987A</sub>-F/pANR-*ftchyA*-R2, pANR-*ftchyA*-F3/pYEU-*ftchyA*-R2, pANR-*ftchyA*-F2/pYEU-*ftchyA*-C<sub>1</sub>\*-R, pYEU-*ftchyA*-C<sub>1</sub>\*-F/pANR-*ftchyA*-R2, pANR-*ftchyA*-F3/pYEU-*ftchyA*-C<sub>T</sub>-H<sub>2075A</sub>-R, pYEU-*ftchyA*-C<sub>T</sub>-H<sub>2075A</sub>-F/pYEU-*ftchyA*-R2. The plasmids pIM 3209-3211 were digested and ligated in to pColdI by same method to generate plasmids pIM 3212-3214, respectively. To express the stand-alone ftChyA-A<sub>1</sub>, ftChyA-A<sub>2</sub> and ftChyA-C<sub>T</sub> domain in *E. coli* BL21, the plasmids pIM 3215-3217 were constructed, respectively. The intron-free *ftchyA*-A<sub>1</sub> was amplified by PCR using primer pairs pColdI-*ftchyA*-A<sub>1</sub>-F/R. The products were digested with *Kpn* I and *EcoR* I, and subsequently inserted into the *Kpn* I and *EcoR* I digested pColdI to create plasmid pIM 3215. The intron-free *ftchyA*-A<sub>2</sub> was amplified by PCR using primer pairs pQ8-*ftchyA*-A<sub>2</sub>-F/R. The products were digested with *EcoR* I and *Not* I, and subsequently inserted into the *EcoR* I and *Not* I digested pQ8 (an expression vector with MBP tag on N-terminus) to yield plasmid pIM 3216. The intron-free *ftchyA*-C<sub>T</sub> was amplified by PCR using primer pairs pColdI-*ftchyA*-C<sub>T</sub>-F/R. The products were digested with *BamH* I and *EcoR* I, and then cloned into pColdI to yield plasmid pIM 3217. The PCR products were amplified by PCR using primer pairs pColdI-*ftchyA*ΔC<sub>T</sub>-F/R and digested with *Spe* I and *EcoR* I. The products were cloned into the *Spe* I and *EcoR* I digested pIM 3208 to generate plasmid pIM 3218. The plasmid pIM 3218 was used to purify the C<sub>T</sub> domain-truncated ftChyAΔC<sub>T</sub> (A<sub>1</sub>-T<sub>1</sub>-C<sub>1</sub>-A<sub>2</sub>-T<sub>2</sub>) from *E. coli* BL21. To express the ftChyA-A<sub>1</sub>T<sub>1</sub> in *E. coli* BL21, the intron-free *ftchyA*-A<sub>1</sub>T<sub>1</sub> was amplified by PCR using primer pairs pColdI-*ftchyA*-A<sub>1</sub>-F/pColdI-*ftchyA*-A<sub>1</sub>T<sub>1</sub>-R. The products were digested with *Kpn* I and *EcoR* I, and then cloned into pColdI to yield plasmid pIM 3219.

To express *NpgA* without N-His tag in *E. coli* BL21, intron-free *NpgA* was cloned from the cDNA of *A. nidulans* by using the primer pairs pET28a-*NpgA*-F/R. The PCR products were digested with *Hind* III and *Nco* I and subsequently inserted into the *Hind*

III and *Nco* I digested pET28a to yield plasmid pIM 3220. To express *NpgA* with N-His tag, intron-free *NpgA* was cloned using the primer pairs pColdI-*NpgA*-F/R. The PCR products were digested with *Sac* I and *Hind* III and subsequently inserted into pColdI to yield plasmid pIM 3221. The plasmid pIM 3222 used for protein expression *ftchyC* in *E. coli* BL21 was constructed by amplifying open reading frames from cDNA reverse transcribed from *A. nidulans* containing *ftchy* cluster using primer pairs pColdI-*ftchyC*-F/R. The PCR products were digested with *Kpn* I and *EcoR* I and subsequently inserted into the *Kpn* I and *EcoR* I digested pColdI to yield plasmid pIM 3222. Intron-free *ftchyD* was cloned from the cDNA of *A. nidulans* containing *ftchy* cluster using the primer pairs pET-Duet-*ftchyD*-F/R. The PCR products were digested with *BamH* I and *Not* I, and subsequently inserted into the *BamH* I and *Not* I digested pET-Duet (an expression vector with His tag on N-terminus) to yield plasmid pIM 3223. Intron-free *ftchyE* was amplified by PCR using primer pairs pQ8-*ftchyE*-F/R. The PCR products were digested with *EcoR* I and *Not* I and subsequently inserted into the *EcoR* I and *Not* I digested pQ8 to yield plasmid pIM 3224. To express *ftchyM* in *E. coli* BL21, intron-free *ftchyM* was cloned using the primer pairs pColdI-*ftchyM*-F/R. The PCR products were digested with *Kpn* I and *BamH* I and subsequently inserted into the *Kpn* I and *BamH* I digested pColdI to yield plasmid pIM 3225. The intron-free *ftchyH* was amplified by PCR using primer pairs pColdI-*ftchyH*-F/R. The fragments were digested with *Kpn* I and *BamH* I and subsequently inserted into the *Kpn* I and *BamH* I digested pColdI to yield plasmid pIM 3226. The *ftchyH* was also cloned into the *EcoR* I and *Not* I digested pQ8 and pGEX-4t-1 (an expression vector with Glutathione S-transferase tag on N-terminus) to create plasmids pIM 3227 and pIM 3228, respectively.

The plasmid used for protein expression of *ftchyH* in *S. cerevisiae* BJ5464-*NpgA* was constructed by amplifying open reading frames from *A. nidulans* containing *ftchy* cluster using primer pairs pYEU-*ftchyH*-F/pYEU-*ftchyH*-R. The fragments were ligated to vector pYEU (an expression vector with Flag tag on N-terminus and His tag on C-terminus) with the promoter ADH<sub>2</sub>P and the terminator ADH<sub>2</sub>T by yeast homologous recombination to obtain plasmid pIM 3229.

All the plasmids were confirmed by DNA sequencing by Sangon Biotech (Shanghai) Co., Ltd.

#### 1.4 The protein expression and purification in *E. coli*

Recombinant plasmids pIM 3208, pIM 3212-3218 and pIM 3221-3228 were transformed into *E. coli* BL21 (DE3) strain by heat shock transformation, respectively. The mono colony was cultivated in liquid LB medium (25 g/L LB broth) with 100 µg/mL ampicillin (for ftChyA and its mutants, *NpgA*, ftChyC, ftChyH-N-His, ftChyH-N-GST, ftChyA-A<sub>1</sub>, ftChyA-C<sub>T</sub>, ftChyM, ftChyD) or 50 µg/mL of kanamycin (for ftChyH-N-MBP, ftChyE, ftChyA-A<sub>2</sub>) at 37 °C overnight. The bacterial solution was then transferred in liquid LB medium (1 L) containing 100 µg/mL ampicillin or 50 µg/mL of kanamycin at 37 °C and 220 rpm to OD<sub>600</sub> of 0.4-0.6. And then, the cultures were maintained at 16 °C for 30 min. Protein expression was induced at 16 °C and 220

rpm for 20 h after adding 0.2 mM isopropylthio- $\beta$ -D-galactoside (IPTG). Cells were collected by centrifugation at 4 °C, 3000 g for 8 min.

The cells of ftChyA were resuspended in 20 mL buffer A (50 mM Tris-HCl, 500 mM NaCl, 10% glycerol, pH 7.5) and were lysed by sonication on ice. Cellular debris were removed by centrifugation at 4 °C, 23000 g for 40 min. The protein was purified by nickel nitrilotriacetic acid (Ni-NTA) agarose resin. And then, the protein was eluted by buffer A containing 250 mM imidazole. The purified protein was passed through a PD-10 desalting column (GE Healthcare) and eluted with buffer C (50 mM Tris-HCl, 50 mM NaCl, 5% glycerol, pH 7.5). The protein was concentrated using ultrafiltration centrifugal tube (Millipore Amicon ® Ultra-15 mL). Finally, the protein was flash frozen in liquid nitrogen and saved at -80 °C. ftChyA mutants, NpgA, ftChyC, ftChyA-A<sub>1</sub>, ftChyA-A<sub>1</sub>T<sub>1</sub>, ftChyA-C<sub>T</sub>, ftChyA $\Delta$ C<sub>T</sub> and ftChyD were treated in the same way. ftChyM was also treated in the same way, but it was resuspended in buffer A containing 1 mM DTT (DL-Dithiothreitol) and eluted buffer containing 250 mM imidazole and 1mM DTT.

ftChyA-A<sub>2</sub> and ftChyE were expressed with N-MBP tag, respectively. The cells of ftChyA-A<sub>2</sub> or ftChyE were resuspended in 20 mL binding buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 1 mM DTT, pH 7.5) and were lysed by sonication on ice. Cellular debris were removed by centrifugation at 4 °C, 23000 g for 40 min. The protein was purified using dextrin sepharose resin. The protein-bound resin was washed with elution buffer (10 mM maltose in binding buffer). The pooled fraction was concentrated and was exchanged into buffer C.

The purified enzyme was analyzed by SDS-PAGE, and the concentration was measured by BCA protein quantification kit (Beijing Dingguo Changsheng Biotechnology Co., Ltd).


### 1.5 The preparation and transformation of *A. nidulans* protoplasts

*A. nidulans* was cultured in solid CD medium containing 10 mM uridine, 5 mM uracil, 1  $\mu$ g/mL pyridoxine HCl and 0.25  $\mu$ g/mL riboflavin at 37 °C for 4 days, and then spores were collected in 20% glycerol. The spores were inoculated in 40 mL liquid CD medium and cultured at 37 °C and 220 rpm for 9 h. After the germination of spores, cultures were centrifuged at 4 °C, 2500 g for 8 min to harvest the mycelia. The precipitation was washed two times with 15 mL osmotic buffer (1.2 M MgSO<sub>4</sub>·7H<sub>2</sub>O, 10 mM sodium phosphate, pH 5.8) at 4 °C, 2500 g for 8 min. Then the precipitation was resuspended with 10 mL osmotic buffer containing 30 mg Lysing Enzymes (Sigma) and 20 mg Yatalase (Takara). The suspension was transferred into 50 mL Erlenmeyer flask, and cultured at 28 °C, 80 rpm for 14 h. The culture fluid was poured directly in a sterile 50 mL centrifugal tube and overlaid gently with 10 mL of trapping buffer (0.6 M sorbitol, 0.1 M Tris-HCl, pH 7.0), then centrifuged at 4 °C, 3000 g for 20 min. The protoplasm layer was transferred and fully scattered into 2  $\times$  STC buffer (1.2 M sorbitol, 10 mM CaCl<sub>2</sub>, 10 mM Tris-HCl, pH 7.5), and centrifuged at 4 °C, 3000 g for 8 min. The supernatant was removed and STC buffer was added to resuspend the protoplasts



for transformation.

## 1.6 MALDI-TOF mass data acquisition



To gain *holo* form of ftChyA-A<sub>1</sub>T<sub>1</sub>, the recombinant plasmids pIM 3219 and pIM 3220 were co-transformed into *E. coli* BL21 (DE3) strain. The mono colony with *ftchyA-A<sub>1</sub>T<sub>1</sub>* and *NpgA* was selected in solid LB medium with 100 µg/mL ampicillin and 50 µg/mL of kanamycin at 37 °C overnight. Protein induction and co-expression of ftChyA-A<sub>1</sub>T<sub>1</sub> and NpgA as described above. The protein of ftChyA-A<sub>1</sub>T<sub>1</sub>-*holo* was purified by Ni-NTA agarose resin. The 50 µL reaction mixture containing 40 µM ftChyA-A<sub>1</sub>T<sub>1</sub>-*holo*, 20 mM Tris-HCl (pH 8.5), 100 mM NaCl, 10 mM MgCl<sub>2</sub>·6H<sub>2</sub>O, 4 mM ATP, 1 mM L-Glu, 1 mM L-Ala and 1 mM Ant for 2 hours at 25 °C.

To analysis of ftChyA-A<sub>1</sub> recognized and loaded amino acid to the Ser binding site (S<sub>800</sub>) of ftChyA-T<sub>1</sub> by MALDI-TOF mass, the following steps will be performed. The 50 µL reaction mixture and 150 µL urea solution (8 M) were added to a 10 kDa ultrafiltration centrifugal tube, and then centrifuged at room temperature (RT), 12,000 g for 20 min. 200 µL urea solution (8 M) was added and centrifuged, which process will be repeated twice. 4 µL DTT (1 M) and 150 µL urea solution (8 M) were added and the nozzle of tube was sealed with parafilm, which incubated at 37 °C for 2 h. Next, 15 µL iodoacetamide solution (1 M) was added and incubated at RT for 1 h in the dark, subsequently centrifuged at RT, 12,000 g for 20 min. 200 µL urea solution (8 M) was added and centrifuged, which process will be repeated twice. 200 µL NH<sub>4</sub>HCO<sub>3</sub> solution (50 mM) was added and centrifuged, which process will be repeated three times. The outer tube of the ultrafiltration centrifugal tube was replaced with a new outer tube. 200 µL trypsin solution (10 µg/mL) was added and the nozzle of tube was sealed with parafilm, which incubated at 37 °C for 36 h to decompose the protease into peptide fragments. The parafilm was removed and centrifuged. 40 µL NH<sub>4</sub>HCO<sub>3</sub> solution (50 mM) was added and centrifuged. The lyophilized peptide sample was

freeze-dried at 4°C. The sample was reconstituted with 200 µL 0.1% TFA (trifluoroacetic acid) and centrifuged with a transient. A Zip Tip C18 micro desalting column was used for desalting peptide fragments. Elution buffer (90% acetonitrile (ACN) with 0.1% TFA) was used to elute the peptide, which was freeze-dried at 4 °C. MALDI-TOF mass data was recorded by a Bruker MALDITOF mass spectrometer Autoflex Speed and  $\alpha$ -cyano-4-hydroxycinnamic acid (CHCA) (Sigma-Aldrich) was used as the matrix for intact precursor peptide. In general, the sample dissolved in 50 µL 0.1% MeOH, and then 2 µL sample was spotted and dried on the target. Subsequently, 2 µL matrix solution (5 mg/mL CHCA dissolved in 50% ACN and 0.1% TFA) was spotted on top of the sample. MALDI-TOF mass data was acquired using the following parameters. Tuning: reflectron; Mass range: 800-2000; Laser diameter: 100 µm; Laser power: 80-100 mV. Cytochrome C and TOFMix™ (SHIMADZU) was used for calibration.

### 1.7 Bioinformatic analysis

To obtain *ftchy* gene cluster from *F. tricinctum* CGMCC 3.4731, we used *chyA* protein sequence from *P. chrysogenum* to retrieve *chyA* orthologues by using local-blast in public fungal genome from NCBI (National Center for Biotechnology Information) database and the private database of our lab. For gene cluster annotation of *ftchy*, 2ndFind program was used to predict the open reading frame and intron. The gene function was assigned based on NCBI Blast search. The domains of ftChyA were analyzed by *interpro* website. Active sites analyses of the ftChyA-C<sub>1</sub>, ftChyA-C<sub>T</sub>, ftChyE, ftChyD and ftChyM were performed using DNAMAN8.0 software, respectively. The conserved domain analysis of ftChyM and ftChyH were performed using NCBI Blast.

To analyze the phylogenetic relationships of ftChyA-C<sub>1</sub> and ftChyA-C<sub>T</sub> domain, multiple sequence alignment of the ftChyA-C<sub>1</sub> and ftChyA-C<sub>T</sub> domain sequences and other C domain sequences (TqaA, AmpA, AmpB, BenZ, PsyA, RoqA, IvoA, SimA, Aba1, EasA, FGSG\_08209, FPSE\_09183, Glip, Sirp, HasD, NFIA\_064400, PENFLA\_c013G03821) obtained from NCBI database were performed using ClustalW. Evolutionary analyses were conducted in MEGA7 software, and the phylogenetic tree was inferred by using neighbor-joining method.

TqaA: ADY16697.1, <https://www.ncbi.nlm.nih.gov/protein/ADY16697.1>.

AmpA: A0A1W6BT53.1, <https://www.ncbi.nlm.nih.gov/protein/A0A1W6BT53.1>.

AmpB: A0A1W6BT46.1, <https://www.ncbi.nlm.nih.gov/protein/A0A1W6BT46.1>.

BenZ: P9WEU9.1, <https://www.ncbi.nlm.nih.gov/protein/P9WEU9.1>.

PsyA: AMQ36132.1, <https://www.ncbi.nlm.nih.gov/protein/AMQ36132.1>.

RoqA: B6HJU6.1, <https://www.ncbi.nlm.nih.gov/protein/B6HJU6.1>.

IvoA: C8V7P4.1, <https://www.ncbi.nlm.nih.gov/protein/C8V7P4.1>.

SimA: CAA82227.1, <https://www.ncbi.nlm.nih.gov/protein/CAA82227.1>.

Aba1: ACJ04424.1, <https://www.ncbi.nlm.nih.gov/protein/ACJ04424.1>.

EasA: C8VPS9.1, <https://www.ncbi.nlm.nih.gov/protein/C8VPS9.1>.

FGSG\_08209: I1RVD9.1, <https://www.ncbi.nlm.nih.gov/protein/I1RVD9.1>.  
FPSE\_09183: K3VDP2.1, <https://www.ncbi.nlm.nih.gov/protein/K3VDP2.1>.  
Glip: Q4WMJ7.1, <https://www.ncbi.nlm.nih.gov/protein/Q4WMJ7.1>.  
Sirp: Q6Q883.1, <https://www.ncbi.nlm.nih.gov/protein/Q6Q883.1>.  
HasD: XP\_754329.2, [https://www.ncbi.nlm.nih.gov/protein/XP\\_754329.2](https://www.ncbi.nlm.nih.gov/protein/XP_754329.2).  
NFIA\_064400: XP\_001263173.1, [https://www.ncbi.nlm.nih.gov/protein/XP\\_001263173.1](https://www.ncbi.nlm.nih.gov/protein/XP_001263173.1).  
PENFLA\_c013G03821: OQE22222.1, <https://www.ncbi.nlm.nih.gov/protein/OQE22222.1>.

The enzyme function initiative-enzyme similarity tool (EFI-EST) was used to generate protein sequence similarity networks (SSNs) of ftChyM with fungal  $\alpha$ -ketoglutarate dependent dioxygenases or the ftChyA-C<sub>1</sub> and ftChyA-C<sub>T</sub> with other fungal C domains. Cytoscape (v3.8.2) software was used for visualizing complex networks of ftChyM or ftChyA-C<sub>1</sub> and ftChyA-C<sub>T</sub>.

2nd Find: <http://biosyn.nih.gov/2ndFind/>.

NCBI BLAST: <https://blast.ncbi.nlm.nih.gov/Blast.cgi>.

interpro website: <http://www.ebi.ac.uk/interpro/search/sequence/>.

initiative-enzyme similarity tool (EFI-EST): <https://efi.igb.illinois.edu/efi-est/>.

## 1.8 Purification and structural characterization of compounds

To isolate **1**, **4**, **5**, **6**, **7**, **8** and **9**, the *AN-ftchyACDEHM* transformants were cultured in 16 L solid CD-ST medium at 25 °C for 4 days. And then, the culture was extracted with ethyl acetate/acetone (v/v, 3/1) for three times. The organic extracts were evaporated to dryness. The extracts were separated by Medium pressure liquid chromatography (MPLC) Reveleris<sup>®</sup> X2 (BUCHI, Switzerland) with a linear gradient of 10% MeOH-H<sub>2</sub>O for 10 min, 10%-50% MeOH-H<sub>2</sub>O in 40 min, 50%-100% MeOH-H<sub>2</sub>O in 15 min, followed by 100% MeOH-H<sub>2</sub>O for 15 min with flow rate of 30 mL/min on C18 column. The fractions containing **1** further separated by semi-preparative HPLC (column: YMC-Pack ODS-A, 5  $\mu$ m, 10  $\times$  250 mm; solvent: MeOH-H<sub>2</sub>O, 35:65; flow: 2.5 mL/min; detector: 210 nm;  $t_R$  = 21.0 min) to yield **1** (10 mg). The compound **4** was purified by HPLC (column: YMC-Pack ODS-A, 5  $\mu$ m, 10  $\times$  250 mm; solvent: MeCN-H<sub>2</sub>O (water with 0.1% v/v formic acid), 26:74; flow: 2.5 mL/min; detector: 210 nm;  $t_R$ =18.0 min) to give **4** (2 mg). The compound **5** was purified by semi-preparative HPLC (column: YMC-Pack ODS-A, 5  $\mu$ m, 10  $\times$  250 mm; solvent: MeCN-H<sub>2</sub>O, 10:90; flow: 2.5 mL/min; detector: 210 nm) to give **5** (4 mg,  $t_R$  = 35.0 min). The compound **6** was further purified by semi-preparative HPLC (column: YMC-Pack ODS-A, 5  $\mu$ m, 10  $\times$  250 mm; solvent: MeOH-H<sub>2</sub>O (water with 0.1% v/v formic acid), 42:58; flow: 2.5 mL/min; detector: 210 nm;  $t_R$  = 30.0 min) to yield **6** (3.7 mg). The compound **7** further purified by semi-preparative HPLC (column: YMC-Pack ODS-A, 5  $\mu$ m, 10  $\times$  250 mm; solvent: MeOH-H<sub>2</sub>O, 18:82; detector: 265 nm) to give **7** (12 mg,  $t_R$  = 33.0 min). The compound **8** (8.8 mg) was isolated using 11 % (v/v) MeCN-H<sub>2</sub>O as the mobile phase by semi-preparative HPLC (column: YMC-Pack ODS-A, 5  $\mu$ m, 10  $\times$  250 mm; flow: 2.5 mL/min; detector: 210 nm;  $t_R$ =45.0 min). The compound **9** (10 mg) was separated

by semi-preparative HPLC (column: YMC-Pack ODS-A, 5  $\mu$ m, 10  $\times$  250 mm; MeCN-H<sub>2</sub>O, 10:90; flow: 2.5 mL/min; detector: 210 nm;  $t_R$ =24.0 min).

To isolate **10**, the *AN-ftchyA* transformants were cultured in 4.8 L solid CD-ST medium containing 10 mM uridine, 5 mM uracil and 0.25  $\mu$ g/mL riboflavin at 25 °C for 4 days. And then, the culture was extracted with MeOH for three times. The extracts were evaporated to dryness. The extracts were separated by Medium pressure liquid chromatography (MPLC) Reveleris<sup>®</sup> X2 (BUCHI, Switzerland) with a linear gradient of 10% MeOH-H<sub>2</sub>O for 10 min, 10%-50% MeOH-H<sub>2</sub>O in 30 min, 50%-100% MeOH-H<sub>2</sub>O in 20 min, followed by 100% MeOH-H<sub>2</sub>O for 20 min with flow rate of 25 mL/min on C18 column. The fractions containing **10** further separated by semi-preparative HPLC (column: YMC-Pack ODS-A, 5  $\mu$ m, 10  $\times$  250 mm; solvent: MeOH-H<sub>2</sub>O (water with 0.1% v/v formic acid), 40:60; flow: 2.5 mL/min; detector: 210 nm;  $t_R$  = 18.0 min) to yield **10** (12 mg). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  12.25 (s, 1H), 8.64 (d,  $J$  = 6.5 Hz, 1H), 8.53 (dd,  $J$  = 8.6, 1.0 Hz, 1H), 7.94 (dd,  $J$  = 7.9, 1.7 Hz, 1H), 7.42 (td,  $J$  = 7.9, 1.7 Hz, 1H), 7.06 (td,  $J$  = 7.6, 1.2 Hz, 1H), 4.20 (m, 1H), 3.64 (dd,  $J$  = 9.4, 4.7 Hz, 1H), 2.54 (m, 1H), 2.45 (m, 1H), 2.18 (m, 1H), 1.82 (m, 1H), 1.35 (d,  $J$  = 7.4 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  171.7, 171.5, 171.4, 169.4, 139.3, 131.7, 131.3, 122.3, 122.0, 118.9, 52.0, 50.4, 29.9, 26.0, 17.3; UV/Vis: 221, 252, 302 nm; HRMS (m/z): [M]<sup>+</sup> calcd. for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>O<sub>6</sub>, 338.1347; found, 338.1346.

To isolate **3**, the large-scale *in vitro* biochemical assays of ftChyA with L-Ala and Ant were performed. The purified 10  $\mu$ M ftChyA was converted to its *holo* form by incubation in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 20  $\mu$ M NpgA, 0.1 mM CoA and 10 mM MgCl<sub>2</sub>·6H<sub>2</sub>O in buffer C (pH 7.5) (total volume 52 mL) at 25 °C for 1 h. Reactions were initiated by the addition of 5 mM ATP, 1 mM Ant and 1 mM L-Ala. The reaction mixture was incubated at 25 °C overnight and then freeze-dried. The products were dissolved in MeOH and purified by semipreparative HPLC with a C18 column (YMC-Pack ODS-A, 5  $\mu$ m, 10  $\times$  250 mm; solvent: MeOH-H<sub>2</sub>O (water with 0.02% v/v formic acid), 25:75; flow: 2.5 mL/min; detector: 210 nm;  $t_R$  = 12.5 min; 2 mg).

To isolate **11** and **2**, the large-scale *in vitro* biochemical assays of ftChyD with **10** and **3** were performed, respectively. The reaction mixture containing 20  $\mu$ M ftChyD, 200  $\mu$ M **10**, 10 mM MgCl<sub>6</sub>·H<sub>2</sub>O, 4 mM ATP, 2 mM L-Gln and 20 mM Tris-HCl (pH 7.5) in buffer C (pH 7.5) (total volume 75 mL) at 25 °C overnight. The reaction mixture containing 20  $\mu$ M ftChyD and 200  $\mu$ M **3** in buffer C (pH 7.5) (total volume 120 mL) under the same conditions. The reaction mixture was freeze-dried, and the products were dissolved in MeOH. Compound **11** was purified by semipreparative HPLC (column: YMC-Pack ODS-A, 5  $\mu$ m, 10  $\times$  250 mm; solvent: MeOH-H<sub>2</sub>O (water with 0.1% v/v formic acid), 20:80; flow: 2.5 mL/min; detector: 210 nm;  $t_R$  = 22.5 min) to yield **11** (4.1 mg). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  11.94 (s, 1H), 8.71 (d,  $J$  = 6.6 Hz, 1H), 8.48 (dd,  $J$  = 8.4, 1.2 Hz, 1H), 8.27 (s, 1H), 7.91 (s, 1H), 7.77 (dd,  $J$  = 8.0, 1.6 Hz, 1H), 7.48 (td,  $J$  = 8.0, 1.5 Hz, 1H), 7.11 (td,  $J$  = 7.6, 1.2 Hz, 1H), 4.20 (m, 1H), 3.30 (t,  $J$  = 6.2 Hz, 1H), 2.44 (t,  $J$  = 7.7 Hz, 2H), 1.98 (m, 1H), 1.90 (m, 1H), 1.32 (d,  $J$  = 7.3

Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  172.6, 171.6, 170.7, 170.0, 139.1, 132.0, 128.5, 122.4, 120.2, 119.9, 53.8, 50.2, 31.7, 26.6, 17.2; UV/Vis: 212, 250, 293 nm; HRMS (m/z):  $[\text{M}]^+$  calcd. for  $\text{C}_{15}\text{H}_{21}\text{N}_4\text{O}_5$ , 337.1506; found, 337.1506.

Compound **2** was separated by semipreparative HPLC (column: YMC-Pack ODS-A, 5  $\mu\text{m}$ , 10  $\times$  250 mm; MeOH- $\text{H}_2\text{O}$  (water with 0.02% v/v formic acid), 5:95; flow: 2.5 mL/min; detector: 210 nm) to yield **2** (3.5 mg,  $t_{\text{R}}$ =12.5 min).

To isolate **14** from large-scale spontaneous conversion of **2** in Tris-HCl buffer (pH 7.5). Compound **2** (3 mg) was added to 500 mL buffer C (pH 7.5). The reaction mixture was kept at 25  $^\circ\text{C}$  for 36 h and extracted with ethyl acetate 4 times. The ethyl acetate layer was evaporated until dry and separated by semipreparative HPLC (column: YMC-Pack ODS-A, 5  $\mu\text{m}$ , 10  $\times$  250 mm; solvent: MeCN- $\text{H}_2\text{O}$  (water with 0.1% v/v formic acid), 12:88; flow: 2.5 mL/min; detector: 210 nm;  $t_{\text{R}}$  = 10 min) to yield **14** (1.6 mg).








## 2. Supplementary Tables

**Supplementary Table 1.** Plasmids used in this study.

Name	Description	Enzyme site	Aim
pIM 3201	<i>fichyA</i> gDNA with downstream 387 bp, in pANR	<i>BamH</i> I	<i>A. nidulans</i> overexpression
pIM 3202	<i>fichyC</i> gDNA with downstream 425 bp, <i>fichyD</i> gDNA with downstream 264 bp, <i>fichyE</i> gDNA with downstream 395 bp, in pANU	<i>Not</i> I	<i>A. nidulans</i> overexpression
pIM 3203	<i>fichyM</i> gDNA with downstream 267 bp, <i>fichyH</i> gDNA with downstream 426 bp, in pANP	<i>BamH</i> I	<i>A. nidulans</i> overexpression
pIM 3204	<i>fichyC</i> gDNA with downstream 425 bp, <i>fichyD</i> gDNA with downstream 264 bp, in pANU	<i>Not</i> I	<i>A. nidulans</i> overexpression
pIM 3205	<i>fichyH</i> gDNA with downstream 426 bp, in pANP	<i>BamH</i> I	<i>A. nidulans</i> overexpression
pIM 3206	<i>fichyM</i> gDNA with downstream 267 bp, in pANP	<i>BamH</i> I	<i>A. nidulans</i> overexpression
pIM 3207	<i>fichyA</i> cDNA in pYEU with Flag and His tag	<i>Spe</i> I- <i>Pml</i> I	To provide <i>fichyA</i> gene
pIM 3208	<i>fichyA</i> cDNA in pColdI with His tag	<i>BamH</i> I- <i>EcoR</i> I	<i>E. coli</i> overexpression
pIM 3209	<i>fichyA-C<sub>1</sub>-H<sub>987A</sub></i> cDNA in pYEU with Flag and His tag	<i>Spe</i> I- <i>Pml</i> I	To provide <i>fichyA-C<sub>1</sub>-H<sub>987A</sub></i> gene
pIM 3210	<i>fichyA-C<sub>T</sub>-H<sub>2074A</sub></i> cDNA in pYEU with Flag and His tag	<i>Spe</i> I- <i>Pml</i> I	To provide <i>fichyA-C<sub>T</sub>-H<sub>2074A</sub></i> gene
pIM 3211	<i>fichyA-C<sub>1</sub>*</i> (A <sub>986</sub> A <sub>987</sub> XXXA <sub>991</sub> ) cDNA in pYEU with Flag and His tag	<i>Spe</i> I- <i>Pml</i> I	To provide <i>fichyA-C<sub>1</sub>*</i> gene
pIM 3212	<i>fichyA-C<sub>1</sub>-H<sub>987A</sub></i> cDNA in pColdI with His tag	<i>BamH</i> I- <i>EcoR</i> I	To prove the active residues of ftChyA-C <sub>1</sub> domain
pIM 3213	<i>fichyA-C<sub>T</sub>-H<sub>2074A</sub></i> cDNA in pColdI with His tag	<i>BamH</i> I- <i>EcoR</i> I	To prove the active residues of ftChyA-C <sub>T</sub> domain
pIM 3214	<i>fichyA-C<sub>1</sub>*</i> (A <sub>986</sub> A <sub>987</sub> XXXA <sub>991</sub> ) cDNA in pColdI with His tag	<i>BamH</i> I- <i>EcoR</i> I	To prove the active residues of ftChyA-C <sub>1</sub> domain
pIM 3215	<i>fichyA-A<sub>1</sub></i> cDNA in pColdI with His tag	<i>Kpn</i> I- <i>EcoR</i> I	<i>E. coli</i> overexpression ftChyA-A <sub>1</sub> domain alone
pIM 3216	<i>fichyA-A<sub>2</sub></i> cDNA in pQ8 with MBP tag	<i>EcoR</i> I- <i>Not</i> I	<i>E. coli</i> overexpression ftChyA-A <sub>2</sub> domain alone
pIM 3217	<i>fichyA-C<sub>T</sub></i> cDNA in pColdI with His tag	<i>BamH</i> I- <i>EcoR</i> I	<i>E. coli</i> overexpression ftChyA-C <sub>T</sub> domain alone
pIM 3218	<i>fichyAΔC<sub>T</sub></i> cDNA in pColdI with His tag	<i>BamH</i> I- <i>EcoR</i> I	To prove the ftChyA-C <sub>T</sub> domain
pIM 3219	<i>fichyA-A<sub>1</sub>T<sub>1</sub></i> cDNA in pColdI with His tag	<i>Kpn</i> I- <i>EcoR</i> I	<i>E. coli</i> overexpression ftChyA-A <sub>1</sub> T <sub>1</sub> domain
pIM 3220	<i>NpgA</i> cDNA in pET28a without His tag	<i>Hind</i> III- <i>Nco</i> I	<i>E. coli</i> overexpression

pIM 3221	<i>NpgA</i> cDNA in pColdI with His tag	<i>Sac</i> I- <i>Hind</i> III	<i>E. coli</i> overexpression
pIM 3222	<i>fichyC</i> cDNA in pColdI with His tag	<i>Kpn</i> I- <i>EcoR</i> I	<i>E. coli</i> overexpression
pIM 3223	<i>fichyD</i> cDNA in pET-Duet with His tag	<i>BamH</i> I- <i>Not</i> I	<i>E. coli</i> overexpression
pIM 3224	<i>fichyE</i> cDNA in pQ8 with MBP tag	<i>EcoR</i> I- <i>Not</i> I	<i>E. coli</i> overexpression
pIM 3225	<i>fichyM</i> cDNA in pColdI with His tag	<i>Kpn</i> I- <i>BamH</i> I	<i>E. coli</i> overexpression
pIM 3226	<i>fichyH</i> cDNA in pColdI with His tag	<i>Kpn</i> I- <i>Hind</i> III	<i>E. coli</i> overexpression
pIM 3227	<i>fichyH</i> cDNA in pQ8 with MBP tag	<i>EcoR</i> I- <i>Not</i> I	<i>E. coli</i> overexpression
pIM 3228	<i>fichyH</i> cDNA in pGEX-4t-1 with GST tag	<i>EcoR</i> I- <i>Not</i> I	<i>E. coli</i> overexpression
pIM 3229	<i>fichyH</i> cDNA in pYEU with Flag and His tag	<i>Spe</i> I- <i>Pml</i> I	<i>S. cerevisiae</i> overexpression

**Supplementary Table 2.** Products from gene (*chyC*, *chyE* and *chyH*) individual KO mutant of *P. chrysogenum*<sup>1</sup>.










Products	Chemical Formula	Molecular Weight	<i>KO chyC</i>	<i>KO chyE</i>	<i>KO chyH</i>
	C <sub>13</sub> H <sub>13</sub> N <sub>3</sub> O <sub>4</sub>	275	√		√
	C <sub>12</sub> H <sub>15</sub> N <sub>3</sub> O <sub>3</sub>	249	√	√	√
	C <sub>13</sub> H <sub>15</sub> N <sub>3</sub> O <sub>5</sub>	293	√	√	√
	C <sub>13</sub> H <sub>14</sub> N <sub>2</sub> O <sub>6</sub>	294	√	√	√
	C <sub>15</sub> H <sub>20</sub> N <sub>4</sub> O <sub>5</sub>	336		√	√
	C <sub>15</sub> H <sub>19</sub> N <sub>3</sub> O <sub>6</sub>	337	√	√	√
	C <sub>10</sub> H <sub>10</sub> N <sub>2</sub> O <sub>2</sub>	190	√	√	√








**Supplementary Table 3.** Analysis of *ftchy* gene cluster from *F. tricinctum*.


Gene	Size(bp)	Gene function	<i>P. chrysogenum</i> (identity/similarity)	<i>F. graminearum</i> (identity/similarity)
<i>ftchyA</i>	7274	NRPS (A <sub>1</sub> -T <sub>1</sub> -C <sub>1</sub> -A <sub>2</sub> -T <sub>2</sub> -C <sub>T</sub> )	64/76	64/78
<i>ftchyC</i>	786	short-chain dehydrogenase (SDR)	79/87	82/91
<i>ftchyD</i>	2287	class II amidotransferase	80/89	87/95
<i>ftchyE</i>	824	glutaminase	31/47	56/74
<i>ftchyH</i>	1743	flavin-dependent oxidase	69/82	74/84
<i>ftchyM</i>	1179	$\alpha$ -KG dioxygenase	71/82	73/83

**Supplementary Table 4.** HRMS data of compounds in this study.

Com.	Structure	Ion Formula	Meas. $m/z$ [M+H] <sup>+</sup>	Meas. $m/z$ [M+Na] <sup>+</sup>	Calc. $m/z$ [M+H] <sup>+</sup>	Calc. $m/z$ [M+Na] <sup>+</sup>	Err (ppm)
1		C <sub>10</sub> H <sub>11</sub> N <sub>2</sub> O <sub>2</sub>	191.0815		191.0815		0.1
2		C <sub>10</sub> H <sub>14</sub> N <sub>3</sub> O <sub>2</sub>	208.1081		208.1081		-0.3
3		C <sub>10</sub> H <sub>13</sub> N <sub>2</sub> O <sub>3</sub>	209.0921		209.0921		-0.4
4		C <sub>10</sub> H <sub>10</sub> N <sub>2</sub> NaO <sub>3</sub>		229.0584		229.0584	0.0
5		C <sub>10</sub> H <sub>12</sub> N <sub>2</sub> NaO <sub>3</sub>		231.0741		231.0740	-0.3
6		C <sub>10</sub> H <sub>9</sub> N <sub>2</sub> O <sub>2</sub>	189.0655		189.0659		2.0
7		C <sub>12</sub> H <sub>15</sub> N <sub>3</sub> NaO <sub>3</sub>		272.1007		272.1006	-0.3
8		C <sub>12</sub> H <sub>14</sub> N <sub>3</sub> O <sub>2</sub>	232.1082		232.1081		-0.8
9		C <sub>7</sub> H <sub>9</sub> N <sub>2</sub> O	137.0706		137.0709		2.8

<b>10</b>		$C_{15}H_{20}N_3O_6$	338.1346		338.1347		0.2
<b>11</b>		$C_{15}H_{21}N_4O_5$	337.1506		337.1506		0.2
<b>14</b>		$C_{10}H_{12}N_3O$	190.0977		190.0975		-0.9
<b>Ant-Me-3</b>		$C_{11}H_{15}N_2O_3$	223.1077		223.1077		0.1
<b>Ant-Me-10</b>		$C_{16}H_{21}N_3NaO_6$		374.1323		374.1323	-0.1


**Supplementary Table 5.** NMR data of compound **1** in DMSO-*d*<sub>6</sub>.



(400 MHz for <sup>1</sup>H NMR, 100 MHz for <sup>13</sup>C NMR)

NO.	$\delta_c$ , type <sup>2</sup>	$\delta_c$ , type	$\delta_H$ (mult, <i>J</i> in Hz) <sup>2</sup>	$\delta_H$ (mult, <i>J</i> in Hz)
1				
2	159.6, C	159.9, C		
3			11.79 (1H, br s, NH)	11.83 (1H, br s, NH)
4	161.4, C	161.7, C		
4a	121.2, C	121.2, C		
5	125.7, CH	125.8, CH	8.10 (1H, d, 7.6)	8.10 (1H, dd, 8.0,1.5)
6	126.2, CH	126.8, CH	7.48 (1H, t, 7.5)	7.48 (1H, t, 8.0)
7	134.3, CH	134.4, CH	7.79 (1H, t, 7.6)	7.79 (1H, td, 8.0,1.5)
8	126.9, CH	126.3, CH	7.63 (1H, d, 8.1)	7.64 (1H, d, 8.0)
8a	148.4, C	148.3, C		
1'	67.1, CH	67.2, CH	4.59 (1H, m)	4.59 (1H, q, 6.6)
2'	21.5, CH <sub>3</sub>	21.6, CH <sub>3</sub>	1.43 (3H, d, 6.6)	1.43 (3H, d, 6.6)
1'-OH			5.65 (1H, d, 7.6)	5.67 (1H, br s)


**Supplementary Table 6.** NMR data of compound **2** in DMSO-*d*<sub>6</sub>.



(400 MHz for <sup>1</sup>H NMR, 100 MHz for <sup>13</sup>C NMR)

NO.	$\delta_{\text{H}}$ (mult, <i>J</i> in Hz)	$\delta_{\text{C}}$ , type	COSY	HMBC
1	12.01 (1H, s)			C2, C8
2		167.9, C		
4		170.4, C		
4a		120.9, C		
5	7.84 (1H, dd, 7.9, 1.5)	128.7, CH	H6	C4, C7, C8a
6	7.20 (1H, td, 8.0, 1.2)	123.5, CH	H5, H7	C4a, C5, C8
7	7.55 (1H, td, 8.0, 1.5)	132.2, CH	H6, H8	C5, C8, C8a
8	8.32 (1H, dd, 8.3, 1.2)	120.8, CH	H7	C4a, C6
8a		138.3, C		
1'	4.18 (1H, q, 7.0)	49.3, CH	H2'	C2', C2
2'	1.49 (3H, d, 7.0)	16.4, CH <sub>3</sub>	H1'	C1', C2
1'-NH <sub>2</sub>	8.31 (2H, overlapped)			
4-NH <sub>a</sub>	7.79 (1H, s)			C4a
4-NH <sub>b</sub>	8.31 (1H, overlapped)			


**Supplementary Table 7.** NMR data of compound **3** in DMSO-*d*<sub>6</sub>.



(400 MHz for <sup>1</sup>H NMR, 100 MHz for <sup>13</sup>C NMR)

NO.	$\delta_{\text{H}}$ (mult, <i>J</i> in Hz)	$\delta_{\text{C}}$ , type	COSY	HMBC
1	11.33 (1H, s)			
2		168.2, C		
4		169.0, C		
4a		118.9, C		
5	8.00 (1H, dd, 7.8, 1.2)	131.1, CH	H6	C4, C7, C8a
6	7.24 (1H, m)	123.8, CH	H5, H7	C4a
7	7.63 (1H, m)	133.7, CH	H6, H8	C5, C8a
8	8.26 (1H, dd, 8.4, 1.2)	121.1, CH	H7	C4a, C6
8a		139.0, C		
1'	4.22 (1H, q, 7.0)	49.3, CH	H2'	C2', C2
2'	1.51 (3H, d, 6.8)	16.5, CH <sub>3</sub>	H1'	C1', C2


**Supplementary Table 8.** NMR data of compound **4** in DMSO-*d*<sub>6</sub>.



(400 MHz for <sup>1</sup>H NMR, 100 MHz for <sup>13</sup>C NMR)

NO.	$\delta_c$ , type <sup>3</sup>	$\delta_c$ , type	$\delta_H$ (mult, <i>J</i> in Hz) <sup>3</sup>	$\delta_H$ (mult, <i>J</i> in Hz)
1			12.65 (1H, s)	12.66 (1H, s)
2	158.6, C	158.7, C		
4	170.2, C	170.3, C		
4a	120.6, C	120.7, C		
5	128.7, CH	128.8, CH	7.84 (1H, dd, 8.2, 1.2)	7.85 (1H, d, 8.0)
6	123.3, CH	123.4, CH	7.20 (1H, td, 8.2, 1.2)	7.21 (1H, t, 8.0)
7	132.2, CH	132.3, CH	7.56 (1H, td, 8.2, 1.2)	7.57 (1H, t, 8.0)
8	119.8, CH	119.8, CH	8.58 (1H, dd, 8.2, 1.2)	8.59 (1H, d, 7.8)
8a	138.0, C	138.1, C		
1'	196.3, C	196.4, C		
2'	24.1, CH <sub>3</sub>	24.1, CH <sub>3</sub>	2.43 (3H, s)	2.42 (3H, s)
4-NH <sub>a</sub>			8.28 (1H, br s)	8.31 (1H, br s)
4-NH <sub>b</sub>			7.73 (1H, br s)	7.77 (1H, br s)

**Supplementary Table 9.** NMR data of compound **5** in DMSO-*d*<sub>6</sub>.




(400 MHz for <sup>1</sup>H NMR, 100 MHz for <sup>13</sup>C NMR)

NO.	$\delta_c$ , type <sup>4</sup>	$\delta_c$ , type	$\delta_H$ (mult, <i>J</i> in Hz) <sup>4</sup>	$\delta_H$ (mult, <i>J</i> in Hz)
1			11.88 (1H, s)	11.99 (1H, s)
2	174.7, C	174.1, C		
4	170.8, C	170.2, C		
4a	121.4, C	120.9, C		
5	128.8, CH	128.5, CH	7.70 (1H, dd, 7.8, 1.5)	7.74 (1H, dd, 7.8, 1.0)
6	123.2, CH	122.4, CH	7.11 (1H, t, 7.8)	7.11 (1H, td, 8.0, 1.0)
7	132.4, CH	131.8, CH	7.46 (1H, dt, 7.8, 1.5)	7.47 (1H, td, 8.0, 1.1)
8	120.4, CH	119.8, CH	8.45 (1H, d, 7.8)	8.57 (1H, d, 8.4)
8a	138.7, C	138.7, C		
1'	68.3, CH	67.9, CH	4.09 (1H, q, 7.0)	4.10 (1H, m)
2'	21.2, CH <sub>3</sub>	20.8, CH <sub>3</sub>	1.28 (3H, d, 7.0)	1.30 (3H, d, 6.8)
1'-OH			6.05 (1H, br s)	5.97 (1H, d, 5.0)
4-NH <sub>a</sub>			8.13 (1H, br s)	8.16 (1H, br s)
4-NH <sub>b</sub>			7.05 (1H, br s)	7.60 (1H, br s)




**Supplementary Table 10.** NMR data of compound **6** in DMSO-*d*<sub>6</sub>.



(400 MHz for <sup>1</sup>H NMR, 100 MHz for <sup>13</sup>C NMR)

NO.	$\delta_c$ , type <sup>5</sup>	$\delta_c$ , type	$\delta_H$ (mult, <i>J</i> in Hz) <sup>5</sup>	$\delta_H$ (mult, <i>J</i> in Hz)
1				
2	147.1, C	147.2, C		
3			12.20 (1H, br s)	12.26 (1H, br s)
4	159.9, C	160.8, C		
4a	123.6, C	123.2, C		
5	126.1, CH	126.1, CH	8.20 (1H, m, H-Ar)	8.19 (1H, dd, 7.9, 1.5)
6	128.8, CH	128.9, CH		7.66 (1H, td, 8.2, 1.5)
7	134.7, CH	134.8, CH	7.40-7.90 (3H, m)	7.91 (1H, td, 8.2, 1.5)
8	128.5, CH	128.5, CH		7.85 (1H, dd, 7.9, 1.5)
8a	147.3, C	147.4, C		
1'	194.0, C	193.9, C		
2'	24.7, CH <sub>3</sub>	24.7, CH <sub>3</sub>	2.70 (3H, s)	2.64 (3H, s)


**Supplementary Table 11.** NMR data of compound **7** in DMSO-*d*<sub>6</sub>.



(400 MHz for <sup>1</sup>H NMR, 100 MHz for <sup>13</sup>C NMR)

NO.	$\delta_c$ , type <sup>6</sup>	$\delta_c$ , type	$\delta_H$ (mult, <i>J</i> in Hz) <sup>6</sup>	$\delta_H$ (mult, <i>J</i> in Hz)
1			12.05 (1H, s)	12.09 (1H, s)
2	171.8, C	171.7, C		
4	170.7, C	170.6, C		
4a	119.7, C	119.6, C		
5	128.7, CH	128.6, CH	7.78 (1H, dd, 7.8, 1.3)	7.80 (1H, dd, 7.8, 0.8)
6	122.4, CH	122.4, CH	7.10 (1H, dd, 7.8, 0.8)	7.11 (1H, td, 7.8, 0.9)
7	132.3, CH	132.2, CH	7.48 (1H, dd, 7.9, 1.3)	7.49 (1H, td, 8.4, 1.2)
8	119.7, CH	119.7, CH	8.53 (1H, dd, 7.9, 0.8)	8.55 (1H, d, 8.4)
8a	139.5, C	139.5, C		
1'	50.1, CH	50.0, CH	4.20 (1H, dq, 7.3, 6.8)	4.21 (1H, m)
2'	17.3, CH <sub>3</sub>	17.3, CH <sub>3</sub>	1.31 (3H, d, 7.3)	1.31 (1H, d, 7.3)
3'			8.47 (1H, d, 6.8)	8.51 (1H, d, 6.8)
4'	169.8, C	169.7, C		
5'	22.7, CH <sub>3</sub>	22.6, CH <sub>3</sub>	1.94 (3H, s)	1.96 (3H, s)
4-NH <sub>a</sub>			8.23 (1H, br s)	8.26 (1H, br s)
4-NH <sub>b</sub>			7.69 (1H, br s)	7.73 (1H, br s)


**Supplementary Table 12.** NMR data of compound **8** in DMSO-*d*<sub>6</sub>.



(400 MHz for <sup>1</sup>H NMR, 100 MHz for <sup>13</sup>C NMR)

NO.	$\delta_c$ , type <sup>7</sup>	$\delta_c$ , type	$\delta_H$ (mult, <i>J</i> in Hz) <sup>7</sup>	$\delta_H$ (mult, <i>J</i> in Hz)
1				
2	159.0, C	158.5, C		
3			12.16 (1H, s)	12.18 (1H, s)
4	162.1, C	161.6, C		
4a	121.6, C	121.1, C		
5	127.4, CH	126.9, CH	8.08 (1H, d, 8.0)	8.09 (1H, dd, 7.8, 1.0)
6	126.8, CH	126.3, CH	7.48 (1H, t, 7.5)	7.48 (1H, t, 7.3)
7	134.9, CH	134.4, CH	7.78 (1H, t, 7.5)	7.79 (1H, td, 7.8, 1.2)
8	126.3, CH	125.8, CH	7.61 (1H, d, 8.0)	7.62 (1H, d, 8.1)
8a	149.1, C	148.6, C		
1'	48.2, CH	47.7, CH	4.72 (1H, m)	4.72 (1H, m)
2'	19.7, CH <sub>3</sub>	19.2, CH <sub>3</sub>	1.38 (3H, d, 7.2)	1.39 (3H, d, 7.0)
3'			8.32 (1H, d, 7.05)	8.34 (1H, d, 7.0)
4'	169.8, C	169.3, C		
5'	23.0, CH <sub>3</sub>	22.5, CH <sub>3</sub>	1.87 (3H, s)	1.88 (3H, s)


**Supplementary Table 13.** NMR data of compound **9** in DMSO-*d*<sub>6</sub>.



(400 MHz for <sup>1</sup>H NMR, 100 MHz for <sup>13</sup>C NMR)


NO.	$\delta_c$ , type <sup>8</sup>	$\delta_c$ , type	$\delta_H$ (mult, <i>J</i> in Hz) <sup>8</sup>	$\delta_H$ (mult, <i>J</i> in Hz)
1	113.7, C	113.7, C		
2	150.1, CH	150.2, CH	6.67 (1H, dd, 7.8, 1.3)	6.67 (1H, dd, 8.2, 1.0)
3	114.3, CH	114.4, CH	7.12 (1H, td, 7.8, 1.3)	7.12 (1H, td, 8.0, 1.4)
4	131.8, CH	131.9, CH	6.47 (1H, td, 7.8, 1.3)	6.47 (1H, td, 8.2, 1.0)
5	116.3, CH	116.4, CH	7.52 (1H, dd, 7.8, 1.3)	7.52 (1H, dd, 8.0, 1.4)
6	128.7, C	128.7, C		
7	171.3, C	171.4, C		
-CONH <sub>a</sub>			7.68 (1H, br s)	7.67 (1H, br s)
-CONH <sub>b</sub>			7.01 (1H, br s)	7.02 (1H, br s)
ArNH <sub>2</sub>			6.53 (2H, br s)	6.53 (2H, br s)

**Supplementary Table 14.** NMR data of compound **10** in DMSO-*d*<sub>6</sub>.




NO.	$\delta_{\text{H}}$ (mult, <i>J</i> in Hz)	$\delta_{\text{C}}$ , type	COSY	HMBC
1	12.25 (s)			C8, C4a, C2
2		171.5, C		
4		169.4, C		
4a		122.0, C		
5	7.94 (dd, 7.9, 1.7)	131.3, CH	H6	C7, C8, C4
6	7.06 (td, 7.6, 1.2)	122.3, CH	H7, H5	C8, C4a, C7, C8a
7	7.42 (td, 7.9, 1.7)	131.7, CH	H6, H8	C8, C6, C5, C8a
8	8.53 (dd, 8.6, 1.0)	118.9, CH	H7	C8a, C6, C5, C4a
8a		139.3, C		
1'	4.20 (m)	50.4, CH	H2'	C2', C2
2'	1.35 (d, 7.4)	17.3, CH <sub>3</sub>		C1', C2
3'	8.64 (d, 6.5)		H1'	C2', C1', C4'
4'		171.4, C		
5'a	2.54 (m)	29.9, CH <sub>2</sub>		C6', C7', C4'
5'b	2.45 (m)			C6', C7', C4'
6'a	2.18 (m)	26.0, CH <sub>2</sub>	H6'b, H5'a, H5'b	C7', C4', C5
6'b	1.82 (m)			C7', C4'
7'	3.64 (dd, 9.4, 4.7)	52.0, CH	H6'a, H6'b	C6', C5', C8'
8'		171.7, C		

**Supplementary Table 15.** NMR data of compound **11** in DMSO-*d*<sub>6</sub>



NO.	$\delta_{\text{H}}$ (mult, <i>J</i> in Hz)	$\delta_{\text{C}}$ , type	COSY	HMBC
1	11.94 (s)			C8, C2
2		171.6, C		
3a	8.27 (s)			C4
3b	7.91 (s)			C4, C4a
4		170.7, C		
4a		120.2, C		
5	7.77 (dd, 8.0, 1.6)	128.5, CH	H6	C4a, C7, C8a, C4
6	7.11 (td, 7.6, 1.2)	122.4, CH	H7, H5	C4a, C5, C7
7	7.48 (td, 8.0, 1.5)	132.0, CH	H6, H8	C8, C5, C8a
8	8.48 (dd, 8.4, 1.2)	119.9, CH	H7	C4a, C6, C8a
8a		139.1, C		
1'	4.20 (m)	50.2, CH		C2', C2
2'	1.32 (d, 7.3)	17.2, CH <sub>3</sub>	H1'	C2, C1'
3'	8.71 (d, 6.6)		H1'	C2', C1', C4'
4'		172.6, C		
5'	2.44 (t, 7.7)	31.7, CH <sub>2</sub>	H6'a, H6'b	C6', C7', C4'
6'a	1.98 (m)	26.6, CH <sub>2</sub>	H7'	C5', C7', C8', C4'
6'b	1.90 (m)		H7'	C5', C7', C8', C4'
7'	3.30 (t, 6.2)	53.8, CH		C6', C5', C8'
8'		170.0, C		


**Supplementary Table 16.** NMR data of compound **14** in DMSO-*d*<sub>6</sub>.




(400 MHz for <sup>1</sup>H NMR, 100 MHz for <sup>13</sup>C NMR)

NO.	δ <sub>c</sub> , type	δ <sub>H</sub> (mult, <i>J</i> in Hz)
2	160.7, C	
4	161.8, C	
4a	121.1, C	
5	125.8, CH	8.10 (1H, m)
6	126.8, CH	7.50 (1H, m)
7	134.4, CH	7.80 (1H, m)
8	126.2, CH	7.63 (1H, m)
8a	148.5, C	
1'	49.8, C	3.90 (1H, m)
2'	21.5, CH <sub>3</sub>	1.36 (3H, s)
1'-NH <sub>a</sub>		8.26 (1H, br s)


### 3. Supplementary Figures




**Raltitrexed**  
anticancer




**Idelalisib**  
antitumor




**Methaqualone**  
sedation and hypnosis




**Albaconazole**  
antifungal




**Ispinesib**  
anticancer




**RBN012759**  
antitumor




**Halofuginone**  
antitumor, antiprotozoan




**Diproqualone**  
antianxiety, analgesia




**Balaglitazone**  
antihyperglycemia




**Mecloqualone**  
sedation




**Tiacrilast**  
antiallergy




**Cloroqualone**  
sedation, antitussive



**Nolatrexed**  
anticancer




**Etaqualone**  
sedation and hypnosis




**Afloqualone**  
sedation, anticancer

Supplementary Fig. 1 Marketed drugs with 4(3H)-quinazolinone scaffold.







**Supplementary Fig. 2** Representative natural 4(3*H*)-quinazolinone peptidyl alkaloids from fungi.




**Supplementary Fig. 3** Representative natural 4(3H)-quinazolinone alkaloids from plants and bacteria.




**Supplementary Fig. 4** Construction of plasmids for overexpression of *ftchy* cluster in *A. nidulans*.




**Supplementary Fig. 5** Confirmation of the on-pathway intermediates of **1** by chemical feeding experiments. The extracted ion chromatograms (EICs) were extracted at  $m/z$  191  $[M + H]^+$  for **1**,  $m/z$  229  $[M + Na]^+$  for **4**,  $m/z$  231  $[M + Na]^+$  for **5**,  $m/z$  189  $[M + H]^+$  for **6**,  $m/z$  272  $[M + Na]^+$  for **7**,  $m/z$  232  $[M + H]^+$  for **8** and  $m/z$  137  $[M + H]^+$  for **9**.




**Supplementary Fig. 6** SDS-PAGE of proteins purified from *E. coli* BL21 in this study. **(a)** ftChyA (264.8 kDa). **(b)** ftChyA-C<sub>1</sub>-H<sub>987</sub>A (264.7 kDa). **(c)** ftChyA-C<sub>1</sub>\* (264.6 kDa). **(d)** ftChyA-C<sub>T</sub>-H<sub>2075</sub>A (264.7 kDa). **(e)** ftChyAΔC<sub>T</sub> (218.1 kDa). **(f)** ftChyA-A<sub>1</sub>T<sub>1</sub>-*holo* (98.34 kDa). **(g)** ftChyA-A<sub>1</sub> (85.7 kDa). **(h)** ftChyA-A<sub>2</sub> (108.3 kDa) with N-MBP tag. **(i)** ftChyA-C<sub>T</sub> (55.2 kDa). **(j)** NpgA (40.1 kDa). **(k)** ftChyC (31.3 kDa). **(l)** ftChyE (73.6 kDa) with N-MBP tag. **(m)** ftChyD (77.6 kDa). **(n)** ftChyM (45.8 kDa). M: marker. All experiments were repeated independently more than three times with similar results.



**Supplementary Fig. 7** ftChyC-catalysed reduction or dehydrogenation reactions with different substrates. The spontaneous cyclization of **4** to form **6** is observed in control experiment.




**Supplementary Fig. 8** Schematic diagrams of ftChyA and its mutants.




**Supplementary Fig. 9** Time-course assays of the stability of **10**. (a) in Tris-HCl buffer (pH 7.5), (b) with ftChyA addition.





**Supplementary Fig.10** LC-MS analyses of the *AN-ftchyA* with feeding different concentrations of Ant.



**Supplementary Fig. 11** Sequence clustering analysis of the *ftChyA-C<sub>1</sub>* and *ftChyA-C<sub>T</sub>* with other fungal C domains. SSN of 273 fungal C domains homologs generated by Cytoscape (v3.8.2). Each node in the network represents a protein sequence and the alignment score is 45.

ftChyA_C1	.EDVYFCPTLCEGNVVALSVSKKFCAYLAFIHRLE..PHVTLIGSLRRRAEAVQACQIMRTRRVTDPPDGS.MFCVVLRESF	75
TqaA_C1	.ENMYFCPTLCEGNVVALSVSKKFCAYLAFIHRLE..PHVTLIGSLRRRAEAVQACQIMRTRRVTDPPDGS.MFCVVLRESF	77
AmpA_C1	.CDYFPGSPICMGLMALSARIPGFSYVAEHTLELP..SSITVGRFRREVGMVESNDVLRTRIVETDE.YGSCVQVNNAPL	76
AmpB_C1	.EDVYFCPTLCEGNVVALSVSKKFCAYLAFIHRLE..PHVTLIGSLRRRAEAVQACQIMRTRRVTDPPDGS.MFCVVLRESF	76
BenZ_C1	.EDVYFCPTLCEGNVVALSVSKKFCAYLAFIHRLE..PHVTLIGSLRRRAEAVQACQIMRTRRVTDPPDGS.MFCVVLRESF	78
PsyA_C1	VEDVYFCPTLCEGNVVALSVSKKFCAYLAFIHRLE..PHVTLIGSLRRRAEAVQACQIMRTRRVTDPPDGS.MFCVVLRESF	78
RoqA_C1	.EDVYFCPTLCEGNVVALSVSKKFCAYLAFIHRLE..PHVTLIGSLRRRAEAVQACQIMRTRRVTDPPDGS.MFCVVLRESF	76
Consensus	pc q g l x z HHxxxD q v	
ftChyA_C1	EWKAVAD.....VSGTSTEIDINCG.EIVRFFLSK...ASR.....LDHHSLSLFEWSLGLILAQVERAYS	133
TqaA_C1	LWDDMNSDIEVNWDMYMKPQPTDALLFGAEIVHAGILAGSDSASESDPSASYVVMHHCICDRWASGLMNNLLEKAYV	157
AmpA_C1	VWAHDTDLAK.....YIELDKIPMQIGDLAHFGIIA...GPTNT.....FVLTTHHSIYGMSTENIFNDLVHAFE	141
AmpB_C1	EWHTAEDLET....YAKEDKARPCAGQLITRYGLVDP..GEGNT.....FVMTTHHAVYDAWTLLETFEDRLKAYK	142
BenZ_C1	KWETSKILFNR...DAFNEKPDLSVDFGLBLAKMSIHRNDTPDQFQ.....LALTMHHSVITGQCRKILDCVEATYH	148
PsyA_C1	AWED.....PS.RCTLEVEFGRFLVFMFALKKDPRTQSC.....LVTMHHALYDPAWSLQILLDQVEATYL	138
RoqA_C1	EFED.....ISGMDCNCPMNLGTEIARVTVYHRGRGSSGSDS....GIFLLTMHHALFDGWVYQLMIGLGLVIYA	141
Consensus	g l hh d	
ftChyA_C1	GEKLEIQ.FSPEVCHLLHQTDSSS.EDFWQCETSEIQVEHFEASARLEQT.AEKVILEHFLHDT.EVSTKYILSSILR	209
TqaA_C1	GDCVITN.SMAFFCQLSDQLASPKTEQWVLLQFNLA.EVGFSLFPFGYTVPSASIHLSIPCQR.DAAGGYTMSNVIR	235
AmpA_C1	GVVFPVTRICRDFKEVVERNADKATEENWVGGEEAEGDMTTFPSLFSASHQLANDSFVHTLQNR.KGSDFTSATILR	220
AmpB_C1	GHEERDITTKKEEYCHMVTIDESES..INFWEEYLAGATRNEFEFSAVSTSKQVADSSVKYSMSLRIDGLSGITVASMIR	221
BenZ_C1	RHITPASPPPTTFMNLRLQ.LPDHK..ENWTSYLSGLNVEVFAILPSSYQFCPTAAATDYLDAD.FNIGRFRSAVLR	224
PsyA_C1	QCSHQSPFPNREVKISKGMSDTKCEERWWEAFAGLADDFEFSFQHTHQREPSVTHRRRTINPAQ.FSRMFRFRSTVAR	217
RoqA_C1	GDKSPRPSKHAANNISKLSIEEG.RSEWSQELKDFQATMEEETSSRRETTSPHWQVRSQCIIIAE..SDMNWLLANKIK	218
Consensus	w fp t	
ftChyA_C1	LAWIILWHCTGHHDDVVEGTVVSGRNATIDGDRLSGEPILATLIVYRIKILATDR..FHESLAQVNNFINMMSCEITGLS	287
TqaA_C1	LAWAMVISCSTSSFDVVFVTVVSGRAAPVADIEEMVAPILAVVPLRVRSPEDE..TIIAAREGIGNQSSENVVAFEGFLG	313
AmpA_C1	AAWSLVQARCDSEFEIVFGTLLSGRNAP.FSNEDSVGAVIAGVFKAKVDGEQ..PVAEWLQQINSHVENTEACNYGLQ	298
AmpB_C1	AAWGLIGSHSEDDVVEGGIVSGRNAPANADKLFGRGIAAVFVYKFPDNDTLITREFVGDVDCSTKVISPEAGLQ	301
BenZ_C1	LAWAITQACQGNHDIYGMVTVSGRNAP.FGILLAMISPTVAMFPRVQINPTA..STEASDELVECTVIRGIEHECTGLQ	302
PsyA_C1	LAWALVQSQCNRTDVEGTVVSGRTAP.SSVESMTGETIAGIEFRVQHPER..TVAQSEELISSTARCMFVECVGME	295
RoqA_C1	LAWTILISSQTHENDVYVGIIVSGRNAP.FEADRVIGPFAAFEFRTQVEDDI..SLEDVQVMRQDVSIMFEFVGLR	296
Consensus	aw v g sgr a a p g	
ftChyA_C1	RIRKQFGNESEACNFCNLLVVOHEQTTESTIFKNPVGSTENMKAFSTFVVLICRPEKSG.SLKMALRDIMTPDAG	366
TqaA_C1	RIRKVSQEDDGGSFQSCQLIVCSWAD.ENRPLINTLEAGSSVVGGAASWALSVCSTDSRENVNTEIPNVISVPGV	392
AmpA_C1	NIARVAEGRPAACNFGSILVICIATS...VAEDSIMQPFAPQANESVVALTECSLAVDGSQIHVHEDTVLPRLEV	374
AmpB_C1	NIRRVSSDPAACDFQTLVVOCHKEK.HLSTEEIDLRAAEADANFSTYALTECSLKSQD.VVCSHDISSLVSKESV	379
BenZ_C1	NIMKMGGEVAAACDFQTLVVICID...GTDYSLLGRPAQETSFSVFCITVILTVCDNVDF.EFKKWWLPQLVPERQV	378
PsyA_C1	HNKNWGEFPAACSFQTLVVCQNER..GAGLEPLGVDEESGNWRAEATYALTVFCDNSAP.FGLEWHPFDIIPAQV	372
RoqA_C1	RIAESSDPAALAGFCNLLIIRLQSLQ.MFFGALIELPENENHDLKFASTYALSVAQQEGTS.LGVKALPNSCILGADRT	374
Consensus	c fq l f	
ftChyA_C1	ESLLRCISQACQLVASEDM.LIGVELMFPQMAKL	402
TqaA_C1	ERLSKHTECVLCFLLTETSL.AIGKVFCISSMMQCL	428
AmpA_C1	QRIVRQTEHVLCQLASAPAG.KLSDEIISPOKKNL	410
AmpB_C1	ERILGCENLLHQMCSSSADKLNELIFISSKQES.	415
BenZ_C1	RLLRCKMKNVVCICTSEAS.TVSDCMTLNPSAAET	414
PsyA_C1	ERLLNCAHIIIEGICHGMNA.SIAD.....	396
RoqA_C1	EALIECDITLLRILREFGT.KMKILRTQLSEWQCL	410
Consensus		

**Supplementary Fig. 12** Sequences alignments of ftChyA-C<sub>1</sub> with other identified fungal NRPS C domains. The black box shows the conserved HHxxxD motif in ftChyA-C<sub>1</sub>.

TqaA: ADY16697.1 (<https://www.ncbi.nlm.nih.gov/protein/ADY16697.1>),


AmpA: A0A1W6BT53.1 (<https://www.ncbi.nlm.nih.gov/protein/A0A1W6BT53.1>),

AmpB: A0A1W6BT46.1 (<https://www.ncbi.nlm.nih.gov/protein/A0A1W6BT46.1>),

BenZ: P9WEU9.1 (<https://www.ncbi.nlm.nih.gov/protein/P9WEU9.1>),

PsyA: AMQ36132.1 (<https://www.ncbi.nlm.nih.gov/protein/AMQ36132.1>),

RoqA: B6HJU6.1 (<https://www.ncbi.nlm.nih.gov/protein/B6HJU6.1>).



**Supplementary Fig. 13** The genome-mined homologous *chy* clusters from different fungi.

ftChyA_CT	IMTINNFYRYLWISLELDGVDNERIKFACNQLVCKHSLRTRVFYTNNDKSVVCLTLRQMPVETVRHSNIESLBEHCIGDS	80
AnChyA_CT	...LRNFYSRYLWISLFGVDQFCILNACNQLVCKHSLRTRVFYTKDEASVQCLTLRQVHVSFIRHYENIEDLDEKCAEDS	77
CoChyA_CT	....NFYSRYLWISLELDHIERIQCAQCRTEKHSILRTRVFYNTTTASVQCLVLRSLVGLRHYKDIESLBEHFTADS	75
PcChyA_CT	.MTLNHYSRYLWISLEFVQNEHLLNACQLVCKHSLRTRVFYTNNDKSVVCLTLRQVFNHVSFHYSNIEINLEKHCACEDS	79
FgChyA_CT	....NFYSRYLWISLELDGVDNERIKAAYNQLVCKHSLRTRVFYTNNDKSVVCLTLRDMFVALTHYADVDMDKHCACEDS	75
FaChyA_CT	.MTLNHYSRYLWISLELDVDEPERIQACIKKIKVHSILRTRVFYTNNDKSVVCLTLRQVFAELVHHSNIESLBEHCASDS	79
FcChyA_CT	....NFYSRYLWISLELDVDEPERLEAAYNQLVCKHSLRTRVFYTNNDKSVVCLTLRDMFVALTHYADVDMDKHCACEDS	75
FpChyA_CT	....NFYSRYLWISLELDVDEPERLEAAYNQLVCKHSLRTRVFYTNNDKSVVCLTLRDMFVALTHYADVDMDKHCACEDS	75
McChyA_CT	.MTLNHYSRYLWISLELDVDEPERLEAAYNQLVCKHSLRTRVFYTNNDKSVVCLTLRNSPVSEFHYSTIKNLEKHCACEDS	79
Consensus	fy ryLw lp l a khs lrtvfy s ql lr h ds	
<b>PHxxxD</b>		
ftChyA_CT	ITTRVVEVGGEGFCICLLKLRD.SRTFLALRLRPHAFDGMSTLSTICDDLSSAYS...GSSIFPCACFSDHRSVRE.RTS	155
AnChyA_CT	LAMEVFNNGEGFCVCLLTLRD.AGRFVLRRLRPHAFDGLSLDIIGSDLSSAYS...GKPLFFCACFSNH.RVWLE.NKT	152
CoChyA_CT	MSHFFPNGAEGFCVCLLTLRD.GQSLRRGCGGRYLRLRPHAFDGLSLDIIGSDLSSAYS...GKPLFFCACFSNH.RVWLE.NKT	155
PcChyA_CT	LAMEVFNNGEGFCVCLLTLRD.SGMYLILRLRPHAFDGMSTLSTICDDLSSAYS...GDSLFFCACFSDHRSVRE.KFI	154
FgChyA_CT	LSMCFVLDGEGFCICLLKLRD.SRKILALRLRPHAFDGMSTLSTICDDLSSAYS...GQEMSPCGCFSDHRSVRE.KFR	150
FaChyA_CT	ITTRVVEVGGEGFCICLLKLRD.SRTFLALRLRPHAFDGMSTLSTICDDLSSAYS...GNVIFPCGCFSDHRSVRE.KTI	154
FcChyA_CT	LAMEVFNNGEGFCICLLKLRD.SRMILALRLRPHAFDGMSTLSTICDDLSSAYS...GQEMSPCGCFSDHRSVRE.KRT	150
FpChyA_CT	LSMCFVLDGEGFCICLLKLRD.SRMILALRLRPHAFDGMSTLSTICDDLSSAYS...GQEMSPCGCFSDHRSVRE.KRT	150
McChyA_CT	LAMEVFNNGEGFCVCFVTLRD.LRTFLILRLRPHAFDGLSLDIIGSDLSSAYS...GNPLTFCACFSDHRSVRE.QRT	154
Consensus	p g q l l lrlpha fdg sl dl ay g pc qfs	
ftChyA_CT	EDANKIKKIVLSLQVTSLS.GKIIINRENIGKSCTRFDNDMLPFRVLTARAEDEFTSEFNSTIMATIVKLAWIITLSRL	234
AnChyA_CT	PETNNIKKIVLGHAEFTSLNKKFLNWRIRGEKENQCMGAHEQFRVYVAIPEVFLSEFNSITIMATIVKLAWIITLSRL	232
CoChyA_CT	FEANQVVRVVLGHAEMTRLD.GQSLRRGDEGQRKEEGEESLGGELSVVAITETAPFLVPAFTIMATIVKLAWIITLSRL	234
PcChyA_CT	EESNNARREVLGNVPMTSNKKYLRLWGSASEMGSFNMGTDLPDQKVVYVAIPEVFLSEFNSITIMATIVKLAWIITLSRL	234
FgChyA_CT	FETVQVVKVVLQDTPIT.....VMSESFPVAKTASACVDEHCLVVAIPEVFLSEFNSITIMATIVKLAWIITLSRL	224
FaChyA_CT	EDTYKIKKIVLQDTPMINS.DKTMNRRERNGEPCATFNNDSPAKVVAIPEVFLSEFNSITIMATIVKLAWIITLSRL	233
FcChyA_CT	FETVQVVKVVLQDTPIT.....VMSESFPVAKAVSTQVDEHCLVVAIPEVFLSEFNSITIMATIVKLAWIITLSRL	224
FpChyA_CT	FETVQVVKVVLQDTPIT.....VMSESFPVAKAASQVDEHCLVVAIPEVFLSEFNSITIMATIVKLAWIITLSRL	224
McChyA_CT	EETIGIKKIVLQDTPMINS.N.EFSRNRDIPDRRDKPKTGMR.EQKVVVAIPEVFLSEFNSITIMATIVKLAWIITLSRL	233
Consensus	p y w vl t N.EFSRNRDIPDRRDKPKTGMR.EQKVVVAIPEVFLSEFNSITIMATIVKLAWIITLSRL	
ftChyA_CT	FPSTCPNDACSDGLSDVVFGQVHGRNLGIPHEDRIVGPCLNIIFVRVHFKSADKHK.....LLSCVQCQCHICMVF	307
AnChyA_CT	ETSTEEEDGCKYGLNDDVVFGQVHGRNLGIPHEDRIVGPCLNIIFVRVHFKLSNKF.....LLSCVQCQCHICMVF	305
CoChyA_CT	FSPKQPNKEGFGERSVVFGQVHGRSLSLPEDRIVGPCLNIIFVRVHLPETAPDLDAVGTRVLEECIQSCHMATLPE	314
PcChyA_CT	ETSTEEEDGAS...DDVVFGQVHGRNLGIPHEDRIVGPCLNIIFVRVHLEFRSNKLE.....LLSCVQCQCHICMSV	304
FgChyA_CT	ETLQND...NSLGDVVFGQVHGRVGLGIPHEDRIVGPCLNIIFVRVHFFSSPEKHE.....LLSCVQCQCHVCMVF	293
FaChyA_CT	FPSTCPNDASEGLSDVVFGQVHGRSLGIPHEDRIVGPCLNIIFVRVHFKPAKHK.....LLSCVQCQCHICMVF	306
FcChyA_CT	ETPQDG...NGLGDVVFGQVHGRVGLGIPHEDRIVGPCLNIIFVRVHFFSSPEKHE.....LLSCVQCQCHVCMVF	293
FpChyA_CT	ETPQDG...NGLGDVVFGQVHGRVGLGIPHEDRIVGPCLNIIFVRVHFFSSPEKHE.....LLSCVQCQCHVCMVF	293
McChyA_CT	ETPTRKSGCGGLNDDVVFGQVHGRGFGIPHEDRIVGPCLNIIFVRVRFPPGSKNF.....LLDQVQCQCHIRMFV	306
Consensus	f vvfqqv hgr edri gpclniiprvr ll q q qh t v	
ftChyA_CT	ENLGLCEIARNCTSWEPGRFSGSFVRFQNFTRNDDTCDFDGRTCETGLFSLPNSPSTANVIVWER.GSLSITMTISS	386
AnChyA_CT	ENLGLCEIIVHNCSTWESGTRFSGSFVRFQNFTRNDDTCDFDGRTCETGLFSLPNSPSTANVIVWER.GSLSITMTISS	384
CoChyA_CT	ENLGLCEITIKHCTHWAPGRFSGSFVRFQNFTRNDDTCDFDGRTCETGLFSLPNSPSTANVIVWER.GSLSITMTISS	394
PcChyA_CT	ENLGLCEIARNCTSWKAGTRFSGSFVRFQNFTRNDDTCDFDGRTCETGLFSLPNSPSTANVIVWER.GSLSITMTISS	383
FgChyA_CT	ENLGLCEIARNCTSWESGTRFSGSFVRFQNFTRNDDTCDFDGRTCETGLFSLPNSPSTANVIVWER.GSLSITMTISS	372
FaChyA_CT	ENLGLCEIARNCTSWEPGRFSGSFVRFQNFTRNDDTCDFDGRTCETGLFSLPNSPSTANVIVWER.GSLSITMTISS	385
FcChyA_CT	ENLGLCEIARNCTSWESGTRFSGSFVRFQNFTRNDDTCDFDGRTCETGLFSLPNSPSTANVIVWER.GSLSITMTISS	372
FpChyA_CT	ENLGLCEIARNCTSWESGTRFSGSFVRFQNFTRNDDTCDFDGRTCETGLFSLPNSPSTANVIVWER.GSLSITMTISS	372
McChyA_CT	ENLGLCEIARNCTSWEPGRFSGSFVRFQNFTRNDDTCDFDGRTCETGLFSLPNSPSTANVIVWER.GSLSITMTISS	384
Consensus	nl i ct w g fgsf rfqnf c g cetgl slpn ps ta vl p li t	
ftChyA_CT	QVDEELAGYVVRVYFSDVIESLAK.....	410
AnChyA_CT	QVDEELAGYVVRVYFSDVIESLAK.....	407
CoChyA_CT	MADEELAGYVVRVYFSDVIESLAK.....	423
PcChyA_CT	QVDEELAGYVVRVYFSDVIESLAK.....	407
FgChyA_CT	EVDEELAGYVVRVYFSDVIESLAK.....	396
FaChyA_CT	QVDEELAGYVVRVYFSDVIESLAK.....	409
FcChyA_CT	EVDEELAGYVVRVYFSDVIESLAK.....	408
FpChyA_CT	EVDEELAGYVVRVYFSDVIESLAK.....	396
McChyA_CT	EVDEELAGYVVRVYFSDVIESLAK.....	424
Consensus	v v l	

**Supplementary Fig. 14** Sequence alignments of ftChyA-C<sub>T</sub> with homologous domains from other *chy* clusters. The black box shows the conserved PHxxxD motif in ftChyA-C<sub>T</sub>.

AnChyA: XP\_015403503.1 ([https://www.ncbi.nlm.nih.gov/protein/XP\\_015403503.1](https://www.ncbi.nlm.nih.gov/protein/XP_015403503.1)),

CoChyA: TDZ15643.1 (<https://www.ncbi.nlm.nih.gov/protein/TDZ15643.1>),


PcChyA: B6HLP9.1 (<https://www.ncbi.nlm.nih.gov/protein/B6HLP9.1>),

FgChyA: I1S3K7.1 (<https://www.ncbi.nlm.nih.gov/protein/I1S3K7.1>),



FaChyA: KIL85360.1 (<https://www.ncbi.nlm.nih.gov/protein/KIL85360.1>),

FcChyA: QPC63060.1 (<https://www.ncbi.nlm.nih.gov/protein/QPC63060.1>),

FpChyA: XP\_009262411.1 ([https://www.ncbi.nlm.nih.gov/protein/XP\\_009262411.1](https://www.ncbi.nlm.nih.gov/protein/XP_009262411.1)),  
McChyA: XP\_002842771.1 ([https://www.ncbi.nlm.nih.gov/protein/XP\\_002842771.1](https://www.ncbi.nlm.nih.gov/protein/XP_002842771.1)).




**Supplementary Fig. 15** The ftChyA-C<sub>T</sub> domain is essential for catalysing the formation of **10** and **3**.




**Supplementary Fig. 16** Bioinformatic analysis of ftChyD. **(a)** Conserved domain analysis of ftChyD. **(b)** Sequence alignments of ftChyD with asparagine synthetase B (AsnB). The black arrow shows the Cys for hydrolysis. The black box shows the conserved ExxDE motif for ATP binding site. AsnB: AJE54988.1 (<https://www.ncbi.nlm.nih.gov/protein/AJE54988.1>).






**Supplementary Fig. 17** Biochemical confirmation of the amidation of ftChyD towards **3**. (a) ftChyD uses  $\text{NH}_4\text{Cl}$  or L-Gln-amide to catalyse the amidation of **3** to form **2**. (b) LC-MS analysis of the incorporation of  $^{15}\text{N}$  into **2**. The EICs were extracted at  $m/z$  209  $[\text{M} + \text{H}]^+$  for **3** and  $^{15}\text{N}$ -labelled **2**, and  $m/z$  208  $[\text{M} + \text{H}]^+$  for **2**. (c) Mass of **2** and  $^{15}\text{N}$ -labelled **2**. (d) HRMS analysis of the incorporation of  $^{15}\text{N}$  into **2**.




**Supplementary Fig. 18** The kinetic parameters of fitChyD toward **3** and **10**. These values were calculated by analyzing production of **2** and **11** by LC-MS analysis. This measurement was conducted in four times.  $K_M$  and  $k_{cat}$  values represent the mean  $\pm$  SEM.







**Supplementary Fig. 20** LC-MS analysis of the *AN-ftchyACDEHM* in  $\text{H}_2^{18}\text{O}$ -medium showing the oxygen atom of the  $\alpha$ -OH group of **1** could be from water. The extracted ion chromatograms (EICs) were extracted at  $m/z$  191  $[\text{M} + \text{H}]^+$  for **1** and  $m/z$  193  $[\text{M} + \text{H}]^+$  for  $^{18}\text{O}$ -labelled **1**.




**Supplementary Fig. 21** Conserved domain analysis of ftChyH and ftChyM. **(a)** ftChyH is a flavin-dependent oxidase that contains a berberine bridge enzyme (BBE) conserved domain. The red box shows that the berberine bridge enzyme (BBE) conserved domain is existed in ftChyH. **(b)** ftChyM is an  $\alpha$ -KGD contains HxD motif and RxS motif. GA4 desaturase: CAD10289.1 (<https://www.ncbi.nlm.nih.gov/protein/CAD10289.1>). The black box shows the HxD motif for binding  $\text{Fe}^{2+}$ . The blue box shows the RxS motif for binding  $\alpha$ -ketoglutarate.



**Supplementary Fig. 22** Sequence clustering analysis of ftChyM with other fungal  $\alpha$ -ketoglutarate dependent dioxygenases. SSN of 239 fungal  $\alpha$ -ketoglutarate dependent dioxygenases homologs generated by Cytoscape (v3.8.2). Each node in the network represents a protein sequence and the alignment score is 60.




**Supplementary Fig. 23** The biochemical assays of ftChyM with different substrates. **(a)** Time course assays of ftChyM with **2**. **(b)** ftChyM catalyse dehydrogenation of **5** to form **4**. **(c)** Time course assays of ftChyM with **11**. **(d)** Time course assays of *in situ* synthesized **12** spontaneously converted to **4** and **6** in room temperature.




**Supplementary Fig. 24** The biochemical assays of ftChyM with **11** in ~80% H<sub>2</sub><sup>18</sup>O-Tris-HCl buffer. **(a)** LC-MS analysis of the ftChyM with **11** in H<sub>2</sub><sup>18</sup>O show that <sup>18</sup>O was incorporated into **4** and **6**. **(b)** Analysis of unlabeled and <sup>18</sup>O-labelled **4** and **6** (in sum). Data was shown as mean ± SEM for 3 independent experiments.







**Supplementary Fig. 25** The proposed mechanism of the (a) ftChyM-catalyzed C-N bond oxidative cleavage **11** to form **4**; (b) the ftChyM-catalyzed oxidative deamination of **2** to form **4**; (c) the alkaline-induced spontaneous C-2-N-3 bond closure of **4** to form **6**.




**Supplementary Fig. 26** Time-course assays of the spontaneous conversion of **4** to **6**.  
**(a)** Tris-HCl buffer (pH 7.5); **(b)** with ftChyM addition.




**Supplementary Fig. 27** Spontaneous cyclization of compound **2**, **5** and **4** in Tris-HCl buffer (pH 7.5). (a) cyclization of **2** to form **14**; (b) cyclization of **5** to form **1**; (c) cyclization of **4** to form **6**.




**Supplementary Fig. 28** Biochemical confirmation of the function of ftChyH. **(a)** LC-MS analyses of the *AN-ftchyACDM* showing elimination of *ftchyH* accumulates **5**. **(b)** Biochemical assay of ftChyH cell-free extracts with **5**, **2** and **11**, respectively. The extracted ion chromatograms (EICs) were extracted at  $m/z$  208  $[M + H]^+$  for **2**,  $m/z$  229  $[M + Na]^+$  for **4**,  $m/z$  231  $[M + Na]^+$  for **5**,  $m/z$  189  $[M + H]^+$  for **6**,  $m/z$  337  $[M + H]^+$  for **11**.




**Supplementary Fig. 29** SDS-PAGE analyses of the expression of ftChyH-His, ftChyH-MBP and ftChyH-GST in *E. coli* BL21, respectively. All experiments were repeated independently more than three times with similar results.




**Supplementary Fig. 30** Biochemical assay of ftChyM with **14** *in vitro*. The extracted ion chromatograms (EICs) were extracted at  $m/z$  190  $[M + H]^+$  for **14** and  $m/z$  189  $[M + H]^+$  for **6**.



**Supplementary Fig. 31** LC-MS analyses of the *A. nidulans* with feeding **2** showing that **2** was converted to **7** by an unknown acetyltransferase of *A. nidulans*. The extracted ion chromatograms (EICs) were extracted at  $m/z$  208  $[M + H]^+$  for **2** and  $m/z$  272  $[M + Na]^+$  for **7**.




**Supplementary Fig. 32** HRMS spectrum (positive ionization) of compound 1.




**Supplementary Fig. 33** HRMS spectrum (positive ionization) of compound 2.







**Supplementary Fig. 34** HRMS spectrum (positive ionization) of compound **3**.




**Supplementary Fig. 35** HRMS spectrum (positive ionization) of compound **4**.




**Supplementary Fig. 36** HRMS spectrum (positive ionization) of compound **5**.




**Supplementary Fig. 37** HRMS spectrum (positive ionization) of compound **6**.




**Supplementary Fig. 38** HRMS spectrum (positive ionization) of compound **7**.




**Supplementary Fig. 39** HRMS spectrum (positive ionization) of compound **8**.




**Supplementary Fig. 40** HRMS spectrum (positive ionization) of compound **9**.




**Supplementary Fig. 41** HRMS spectrum (positive ionization) of compound **10**.




**Supplementary Fig. 42** HRMS spectrum (positive ionization) of compound 11.




**Supplementary Fig. 43** HRMS spectrum (positive ionization) of compound 14.




**Supplementary Fig. 44** HRMS spectrum (positive ionization) of compound Ant-Me-3.



**Supplementary Fig. 45** HRMS spectrum (positive ionization) of compound Ant-Me-10.




Supplementary Fig. 46  $^1\text{H}$  NMR spectrum of compound **1** in  $\text{DMSO-}d_6$  (400 MHz).




Supplementary Fig. 47  $^{13}\text{C}$  NMR spectrum of compound **1** in  $\text{DMSO-}d_6$  (100 MHz).







Supplementary Fig. 48  $^1\text{H}$  NMR spectrum of compound **2** in  $\text{DMSO-}d_6$  (400 MHz).




Supplementary Fig. 49  $^{13}\text{C}$  NMR spectrum of compound **2** in  $\text{DMSO-}d_6$  (100 MHz).




**Supplementary Fig. 50** HMBC spectrum of compound **2** in DMSO-*d*<sub>6</sub>.




**Supplementary Fig. 51** HSQC spectrum of compound **2** in DMSO-*d*<sub>6</sub>.




**Supplementary Fig. 52**  $^1\text{H}$ - $^1\text{H}$ -COSY spectrum of compound **2** in  $\text{DMSO-}d_6$ .



**Supplementary Fig. 53**  $^1\text{H}$  NMR spectrum of compound **3** in  $\text{DMSO-}d_6$  (400 MHz).




Supplementary Fig. 54  $^{13}\text{C}$  NMR spectrum of compound 3 in  $\text{DMSO-}d_6$  (100 MHz).




Supplementary Fig. 55 HMBC spectrum of compound 3 in DMSO- $d_6$ .







Supplementary Fig. 56 HSQC spectrum of compound 3 in DMSO- $d_6$ .




**Supplementary Fig. 57**  $^1\text{H}$ - $^1\text{H}$ -COSY spectrum of compound **3** in  $\text{DMSO-}d_6$ .




Supplementary Fig. 58  $^1\text{H}$  NMR spectrum of compound **4** in  $\text{DMSO-}d_6$  (400 MHz).




**Supplementary Fig. 59**  $^{13}\text{C}$  NMR spectrum of compound 4 in  $\text{DMSO-}d_6$  (100 MHz).




Supplementary Fig. 60  $^1\text{H}$  NMR spectrum of compound **5** in  $\text{DMSO-}d_6$  (400 MHz).



Supplementary Fig. 61  $^{13}\text{C}$  NMR spectrum of compound **5** in  $\text{DMSO-}d_6$  (100 MHz).




Supplementary Fig. 62  $^1\text{H}$  NMR spectrum of compound **6** in  $\text{DMSO-}d_6$  (400 MHz).




**Supplementary Fig. 63**  $^{13}\text{C}$  NMR spectrum of compound 6 in  $\text{DMSO-}d_6$  (100 MHz).







Supplementary Fig. 64  $^1\text{H}$  NMR spectrum of compound 7 in  $\text{DMSO-}d_6$  (400 MHz).




**Supplementary Fig. 65**  $^{13}\text{C}$  NMR spectrum of compound 7 in  $\text{DMSO-}d_6$  (100 MHz).




Supplementary Fig. 66  $^1\text{H}$  NMR spectrum of compound **8** in  $\text{DMSO-}d_6$  (400 MHz).




Supplementary Fig. 67  $^{13}\text{C}$  NMR spectrum of compound **8** in  $\text{DMSO-}d_6$  (100 MHz).




**Supplementary Fig. 68**  $^1\text{H}$  NMR spectrum of compound **9** in  $\text{DMSO-}d_6$  (400 MHz).



**Supplementary Fig. 69**  $^{13}\text{C}$  NMR spectrum of compound **9** in  $\text{DMSO-}d_6$  (100 MHz).




Supplementary Fig. 70  $^1\text{H}$  NMR spectrum of compound **10** in  $\text{DMSO-}d_6$  (400 MHz).




Supplementary Fig. 71  $^{13}\text{C}$  NMR spectrum of compound **10** in  $\text{DMSO-}d_6$  (100 MHz).







Supplementary Fig. 72 HMBC spectrum of compound 10 in DMSO- $d_6$ .




Supplementary Fig. 73 HSQC spectrum of compound **10** in DMSO-*d*<sub>6</sub>.




Supplementary Fig. 74  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of compound **10** in  $\text{DMSO-}d_6$ .




**Supplementary Fig. 75** DEPT-135° spectrum of compound **10** in DMSO-*d*<sub>6</sub>.




Supplementary Fig. 76  $^1\text{H}$  NMR spectrum of compound **11** in  $\text{DMSO-}d_6$  (400 MHz).



Supplementary Fig. 77 <sup>13</sup>C NMR spectrum of compound **11** in DMSO-*d*<sub>6</sub> (100 MHz).




Supplementary Fig. 78 HMBC spectrum of compound 11 in DMSO- $d_6$ .




Supplementary Fig. 79 HSQC spectrum of compound **11** in DMSO-*d*<sub>6</sub>.







Supplementary Fig. 80  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of compound **11** in  $\text{DMSO-}d_6$ .




**Supplementary Fig. 81** DEPT-135° spectrum of compound **11** in DMSO-*d*<sub>6</sub>.



**Supplementary Fig. 82**  $^1\text{H}$  NMR spectrum of compound **14** in  $\text{DMSO-}d_6$  (400 MHz).



Supplementary Fig. 83  $^{13}\text{C}$  NMR spectrum of compound **14** in  $\text{DMSO-}d_6$  (100 MHz).



**Supplementary Fig. 84** An efficient self-circulation system among ftChyA, ftChyD and ftChyM-catalysed reactions.

## 4. Supplementary References

1. Viggiano, A. et al. Pathway for the biosynthesis of the pigment chrysogine by *Penicillium chrysogenum*. *Appl. Environ. Microbiol.* **84**, e02246-17 (2018).
2. Zhuo, S. et al. Chemical profile of the secondary metabolites produced by a deep-sea sediment-derived fungus *Penicillium commune* SD-118\*. *CHIN. J. OCEANOL. LIMNOL.*, **30**, 305-314 (2012).
3. Tezuka, Y. et al. Studies on the metabolites of mycoparasitic fungi. I. metabolites of *Cladobotryum varium*. *Chem. Pharm. Bull.* **42**, 2612-2617 (1994).
4. Thi, Q.V. et al. Secondary metabolites from an actinomycete from vietnam's east sea. *Nat. Prod. Commun.* **11**, 401-404 (2016).
5. Bergman J. et al. Synthesis of chrysogine, a metabolite of *Penicillium chrysogenum* and some related 2-substituted 4-(3*H*)-quinazolinones. *Tetrahedron.* **46**, 1295-1310 (1990).
6. Onuki, H., Miyashige, H., Hasegawa, H. & Yamashita, S. NI15501A, a novel anthranilamide derivative from a marine fungus *Penicillium* sp. *J. Antibiot. (Tokyo)*. **51**, 442-444 (1998).
7. Jankowski, F. et al. Efficient microwave-assisted two-step procedure for the synthesis of 1,3-disubstituted-imidazo[1,5-a]quinazolin-5-(4*H*)-ones. *Tetrahedron* **66**, 128-133 (2010).
8. Chen, GD. et al. Benzamides and quinazolines from a mangrove actinomycetes *Streptomyces* sp. (No. 061316) and their inhibiting caspase-3 catalytic activity *in vitro*. *Chem. Pharm. Bull. (Tokyo)*. **59**, 447-451 (2011).